
Dale J. Pullen
PROFESSOR EMERITUS
Department:
SOM-Pediatrics
Email:
jpullen@umc.edu
Biography
Dr. Pullen served as Director of the UMMC Division of Pediatric Hematology/Oncology and Director of the MS Children’s Cancer Clinic from 1969 through 2005. Since January 2006, she has worked part time at UMMC as Emeritus Professor, Department of Pediatrics, Division of Pediatric Hematology/Oncology.
Dr. Pullen’s primary research interest has been in the classification and treatment of childhood acute lymphocytic leukemia (ALL) through her work in the national Pediatric Oncology Group (POG), and the Children’s Oncology Group (COG).
Education
University of Tennessee Health Sciences Ctr, Memphis TN, MD, NIH Postdoctoral Traineeship in Pediatric Hematology/Oncology | 1969 |
University of Tennessee Health Sciences Ctr, Memphis TN, MS Degree obtained during fellowship training, Pediatrics | 1969 |
Charity Hospital of LA, Tulane University School of Medicine, New Orleans LA, Residency in Pediatrics | 1964 |
Parkland Memorial Hospital, Dallas TX, Internship (Rotating) | 1962 |
Tulane University School of Medicine, New Orleans LA, MD, Medicine | 1961 |
Millsaps College, Jackson MS, BS, Chemistry | 1957 |
Specialty Certification Licensure
Re-certification, American Board of Pediatrics, Subboard of Pediatric Hematology/Oncology | 06/1999 - Present |
Certification, Certification (permanent), American Board of Pediatrics, Subboard of Pediatric Hematology/Oncology | 11/1974 - Present |
Certification, Certification (permanent), American Board of Pediatrics | 10/1969 - Present |
Licensure, Mississippi State Medical License | 1969 - Present |
Licensure, Tennessee State Medical License | 1966 - Present |
Licensure, Louisiana State Medical License | 1961 - Present |
Current Positions
Professor Emeritus, School of Medicine, Department of Pediatrics | 2006 - Present |
The University of Mississippi Medical Center Jackson, Mississippi 39216 |
Academic Appointments or Other Previous Appointments
Billy S. Guyton (formerly F.A.P. Barnard) Distinguished Professor, University of Mississippi Medical Center, School of Medicine | 1993 - 12/1998 |
Professor, University of Mississippi Medical Center, School of Medicine, Department of Pediatrics | 06/1982 - 12/2005 |
Associate Professor, University of Mississippi Medical Center, School of Medicine, Department of Pediatrics | 06/1975 - 06/1982 |
Assistant Professor, University of Mississippi Medical Center, School of Medicine, Department of Pediatrics | 07/1969 - 06/1975 |
Sponsored Program Funding
Extramural, Children's Oncology Group Phase I/Pilot Consortium, National Cancer Institute | 08/2003 - 07/2006 |
Extramural, Pediatric Oncology Group ALinC 16/17 Classificiation, National Cancer Institute | 03/2003 - 04/2005 |
Extramural, Children's Oncology Group, National Cancer Institute | 01/2003 - 10/2005 |
Extramural, Children's Oncology Group Phase I/Pilot Consortium Per Case Reimbursement, National Cancer Institute | 01/2003 - 09/2005 |
Extramural, Children's Oncology Group Per Case Reimbursement, National Cancer Institute | 01/2002 - 09/2005 |
Extramural, Pediatric Oncology Group, National Cancer Institute | 09/1974 - 12/2003 |
Publications
Journal Article | |
Asselin BL, Devidas M, Chen L, Franci VL, Pullen J, Borowitz MJ, Hutchinson RE, Ravindranath Y, Armenian SH, Camitta MB, Lipshultz SE Cardioprotection and safety of dexrazoxane in patients treated for newly diagnosed T-cell acute lymphoblastic leukemia or advanced-stage lymphoblastic non-Hodgkin lymphoma: a report of the Children's Oncology Group randomized trial Pediatric Oncology Group 9404 J of Clin Oncol 2016; 34(8):854-862 | 2016 |
Sitthi-Amorn J, Herrington B, Megason G, Pullen J, Gordon C, Hogan S, Koganti T, Hicks C Transciptome analysis of minimal residual disease in subtypes of pediatric B Cell Acute Lymphoblastic Leukemia Clinical Medicine Insights: Oncology 2015; 951-960 | 2015 |
Dreyer ZE, Hilden JM, Jones T, Devidas M, Winick NJ, Willman CL, Harvey RC, Chen I-M, Behn FG, Pullen J, Wood BL, Carroll AJ, Heerema NA, Felix CA, Robinson B, Reaman GH, Salzer WL, Hunger SP, Carroll WL, Camitta BM Intensified chemotherapy without SCT in infant ALL: Results from COG P9407 (Cohort 3) Pediatr Blood Cancer 2015; 62:419-426 | 2015 |
Tower RL, Jones T, Camitta BM, Asselin B, Bell B, Chauvenet A, Defidas M, Halperin E, Pullen J, Shister J, Taylor S, Winich N, Kurtzberg J Dose intensification of methotrexate and cytarabine during intensivied continuation chemotherapy for high-risk B-precursor acute lymphoblastic leukemia: POG 9406: A randomized study conducted by the Pediatric Hematology/Oncology Group J Pediatr Hematol Oncol 2014; 36(5):353-361 | 2014 |
Chen I, Harvey RC, Mullighan CG, Gastier-Foster J, Wharton W, Kang H, Borowitz MJ, Camitta BM, Carroll AJ, Devidas M, Pullen DJ, Payne-Turner D, Tasian SK, Reshmi S, Cottrell CE, Reaman GH, Bowman WP, Carroll WL, Loh ML, Winick NH, Hunger SP, Willman CL Outcome modeling with CRLF2, IKZF1, JAK and minimal residual disease in pediatric acute lymphoblastic leukemia: A Children's Oncology Group study Blood, 2012; 119(15):3512-3522 | 2012 |
Bowman WP, Larsen E, Devidas M, Linda SB, Blach L, Carroll AJ, Carroll WL, Pullen J, Shuster J, Willman CL, Winich N, Camitta B, Hunger S, Borowitz M Influence of minimal residual disease (MRD) on outcomes in children with high risk acute lymphocytic leukemia: Results of Pediatric Oncology Group trial 9906 Pediartr Blood Cancer, 2011; 57(4):569-577 | 2011 |
Asselin BL, Devidas M, Wang C, Pullen J, Borowitz MJ, Hutchinson R, Lipshultz SE, Camitta BM Effectiveness of high dose methotrexate in T-cell lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: A randomized study by the Children's Oncology Group (POG 9404) Blood, 2011; 118(4), 874-882 | 2011 |
Maloney KW, Carroll WL, Carroll AJ, Devidas M, Borowitz MJ, Martin PL, Pullen J, Whitlock JA, Willman CL, Winick NJ, Camitta BM, Hunger SP: Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome: A report from the Children's Oncology Group Blood, 2010; 116(7):1045-1050 | 2010 |
Salzer WL, Devidas M, Carroll WL, Winick N, Pullen J, Hunger SP, Camitta BM: Long-term results of the Pediatric Oncology Group studies for childhood acute lymphoblastic leukemia 1984-2001: A report from the Children's Oncology Group Leukemia, 2010; 24:355-370 | 2010 |
Rubnitz JE, Wichlam D, Devidas M, Shuster J, Linda SB, Kurtzberg J, Bell B, Hunger SP, Chauvenet A, Pui C-H, Camitta B, Pullen J: Prospective analysis of TEL gene rarrangements in childhood acute lymphoblastic leukemia: a Children's Oncology Group study Journal of Clinical Oncology, 2008; 26:2186-2191 | 2008 |
Borowitz MJ, Devidas M, Hunger SP, Bowman WP, Carroll AJ, Carroll WL, Martin PL, Pullen DJ, Viswanatha D, Willman CL, Winick H, Camitta B: Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors. A Children's Oncology Group study Blood, 2008; 111(12):5477-5485 | 2008 |
Elkin TD, Jenso SA, McNeil L, Gilbert ME, Pullen J, McComb L Religiosity and coping in mothers of children diagnosed with cancer: An exploratory analysis. J Pediatr Oncol Nursing. 2007;24:274-278 | 2007 |
Heerema NA, Raimondi SC, Biegel J, Camitta BM, Cooley LD, Gaynon PS, Hirsch B, Magenis HE, McGavran L, Patil S, Pettenati MJ, Pullen J, Rao K, Roulston D, Schneider NR, Shuster JJ, Sanger W, Sather H, Sutcliffe MJ, van Tuinen P, Watson MS, Carroll AJ: Specific extra chromosomes occur in modal number dependent pattern in pediatric acute lymphoblastic leukemia Genes, Chromosomes and Cancer, 2007; 46(7):684-693 | 2007 |
Schultz KR, Pullen J, Sather HN, Shuster JJ, Devidas M, Borowitz MJ, Carroll AJ, Heerema NA, Rubnitz JE, Loh ML, Raetz EA, Winick NJ, Hunger SP, Carroll WL, Gaynon PS, Camitta BM: Risk and response-based classification of childhood B-precursor acute lymphoblastic leukemia: A combined analysis of prognostic markers from the Pediatric Oncology Group and Children's Cancer Group Blood, 2007; 109:926-935 | 2007 |
Chauvenet A, Martin P, Devidas M, Bell B, Kurtzberg J, Pullen J, Pettenati M, Carroll AJ, Shuster J, Camitta B: Anti-metabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: Pediatric Oncology Group study 9201 Blood, 2007; 110:1105-1111 | 2007 |
Wacker P, Land VJ, Camitta BM, Kurtzberg J, Pullen J, Harris MB, Shuster JJ: Allergic reactions to E.coli L-asparaginase do not affect outcome in childhood B-precursor acute lymphoblastic leukemia: a Children's Oncology Group study J Pediatr Hematol Oncol, 2007; 29(9):627-632 | 2007 |
Barredo JC, Devidas M, Lauer SJ, Billett A, Marymont MA, Pullen J, Camitta B, Winick N, Carroll W, Ritchey A Isolated CNS relapse of acute lymphoblastic leukemia treated with intensive systemic chemotherapy and delayed CNS irradiation: A Pediatric Oncology Group Study. J Clin Onco1, 2006;24(19):3142-3149 | 2006 |
Bomgaars LR, Megason GC, Pullen J, Langevin AM, Kuhn J, Bernstein M, Blaney SM: Phase I trial of MGI 114 in pediatric patients with solid tumors Pediatric Blood & Cancer, 2006; 47(2):163-168 | 2006 |
Mehta PA, Davies SM, Kumar A, Devidas M, Lee S, Wilke T, Elliott J, Villaneuva J, Pullen J, Zewge Y, Filipovich A: Perforin polymorphism A91V and susceptibility to childhood acute lymphoblastic leukemia Leukemia, 2006; 20(9):1539-1541 | 2006 |
Sutcliffe MJ, Shuster JJ, Sather HN, Camitta BM, Pullen J, Schultz KR, Borowitz MJ, Gaynon PS, Carroll AL, Heerema NA High concordance from independent studies by the Children’s Cancer Group and Pediatric Oncology Group associating favorable prognosis with combined trisomies 4, 10, and 17 in children with NCI standard risk B-precursor acute lymphoblastic leukemia: A Children’s Oncology Group initiative. Leukemia. 2005;19:734-740 | 2005 |
Savasan S, Buck S, Ozdemir O, Hamre M, Asselin B, Pullen J, Ravindranath Y: Evaluation of cytotoxicity by flow cytometric drug sensitivity assay in childhood T-cell acute lymphobalstic leukemia Leuk Lymphoma, 2005; 46(6) 833-841 | 2005 |
Sutcliffe MJ, Shuster JJ, Sather HN, Camitta BM, Pullen J, Schultz KR, Borowitz MJ, Gaynon PS, Carroll AL, Heerema NA: High concordance from independent studies by the Children’s Cancer Group and Pediatric Oncology Group associating favorable prognosis with combined trisomies 4, 10, and 17 in children with NCI standard risk B-precursor acute lymphoblastic leukemia: A Children’s Oncology Group initiative Leukemia, 2005; 19:734-740 | 2005 |
Stoppelbein L, Greening L, Jordan SS, Elkin TD, Moll G, Pullen J: Factor analysis of the Pediatric Symptom Checklist with a chronically ill pediatric population J Dev Behav Pediatr, 2005; 26(5):349-361 | 2005 |
Borowitz MJ, Pullen DJ, Winick N, Martin PL, Bowman WP, Camitta B Comparison of diagnostic and relapse flow cytometry phenotypes in childhood acute lymphoblastic leukemia: Implications for residual disease detection: A report from the Children's Oncology Group Cytometry & Clin Cytom, 2005; 68(1):18-24 | 2005 |
Whitehead VM, Shuster JJ, Vuchich M-J, Mahoney DH, Lauer SJ, Payment C, Kock PA, Cooley LD, Look At, Pullen DJ, Camitta B: Accumulation of methotrexate and methotrexate polyglutamates in lymphoblasts and treatment outcome in children with B-progenitor cell acute lymphoblastic leukemia: A Pediatric Oncology Group study Leukemia, 2005; 19:533-536 | 2005 |
Diccianni MB, Yu J, Meppelink G, de Vries M, Shao L-E, Gebauer G, Shih H, Roberts W, Kilcoin N, Pullen J, Carson DA, Yu AL 3-amino thioacridone inhibits DNA synthesis and induces DNA damage in T-cell acute lymphoblastic leukemia (T-ALL) in p-16 dependent manner. J Exp Therapeutics Oncology. 2004;4:223-237 | 2004 |
Heerema NA, Harbott J, Galimberti S, Camitta B, Gaynon P, Janka-Schaub G, Kamps W, Basso G, Pui C, Schrappe M, Auclerc M. Carroll A, Conter V, Harrison C, Pullen J, Raimondi S, Richards S, Riehm H, Sather H, Shuster J, Silverman L, Valsecchi M, Arico M: Secondary cytogenetic aberrations in childhood Philadelphia chromosome positive acute lymphoblastic leukemia are non random and may be associated with outcome Leukemia, 2004; 18:693-702 | 2004 |
Borowitz MJ, Pullen DJ, Shuster J, Viswanatha D, Montgomery K, Willman CL, Camitta B: Minimal residual disease detection in childhood precursor-B-cell acute lymphoblastic leukemia: Relation to other factors. A Children's Oncology Group study Leukemia, 2003; 17:1566-1572 | 2003 |
Applegate H, Webb P, Elkin TD, Neul S, Drabman R, Moll, Jr G, Pullen J, Smith MG, Iyer R, Megason G: Improving Parent Participation at Pediatric Diabetes and Sickle Cell Appointments Using a Brief Intervention Children's Health Care , 2003; 32(2): 125-136 | 2003 |
Pui C-H, Chessells JM, Camitta B, Baruchel A, Biondi A, Boyett JM, Carroll A, Eden OB, Evans WE, Gadner H, Harbott J, Harms DO, Harrison CJ, Harrison PL, Heerema N, Janka-Schaub G, Kamps W, Masera G, Pullen J, Raimondi SC, Richards S, Riehm H, Sallan S, Sather H, Shuster J, Silverman LB, Valsecchi MG, Vilmer E, Zhou Y, Gaynon PS, Schrappe M: Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements Leukemia, 2003; 17:700-706 | 2003 |
Winter SS, Sweatman J, Shuster JJ, Link MP, Amylon MD, Pullen J, Camitta BM, Larson RS: Bone marrow stroma-supported culture of T-lineage acute lymphoblastic leukemia cells predicts treatment outcome in children: A Pediatric Oncology Group study Leukemia, 2002; 16(6):1121-1126 | 2002 |
Shuster J, Link M, Camitta B, Pullen J, Behm F: Minimax two-stage designs with applications to tissue banking case-control studies Statistics in Medicine, 2002; 21(17):2479-2493 | 2002 |
Pui CH, Gaynon PS, Boyett JM, Chessells JM, Baruchel A, Kamps W, Silverman LB, Biondo A, Harms DO, Vilmer E, Schrappe M, Camitta B, Masera G, Riehm H, Harbott J, Harrison C, Eden OB, Carroll A, Heerema N, Pullen J, Sather H, Shuster J Outcome of treatment of childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet. 2002;359(9321):1909-1915 | 2002 |
Shao L, Diccianni MB, Tanaka T, Gribi R, Yu AL, Pullen DJ, Camitta BM, Yu J: Thioredoxin expression in primary T-cell acute lymphoblastic leukemia and its therapeutic implication Cancer Res, 2001; 64:7333-7338 | 2001 |
Whitehead VM, Payment C, Cooley L, Lauer SJ, Mahoney DJ, Shuster JJ, Vuchich MJ, Bernstein ML, Look AT, Pullen DJ, Camitta BM: The association of the TEL-AML1 chromosomal translocation with the accumulation of methotrexate polyglutamates in lymphoblasts and with ploidy in childhood B-progenitor cell acute lymphoblastic leukemia: A Pediatric Oncology Group study Leukemia, 2001; 15(7):1081-1088 | 2001 |
Lauer SJ, Shuster JJ, Mahoney DH, Winick N, Toledano S, Munoz L, Kiefer G, Pullen J, Steuber CP, Camitta BM: A comparison of early intensive methotrexate/mercaptopurine with early intensive alternating combination chemotherapy for high-risk B-precursor acute lymphoblastic leukemia: A Pediatric Oncology Group phase III randomized trial Leukemia, 2001; 15:1038-1045 | 2001 |
Shah SJ, Taub JW, Witt TL, Pollock BH, Ding BC, Moore DS, Amylon M, Pullen J, Ravindranath Y, Matherly LH: Relationship of p15 and p16 gene altrations to elevated dihydrofolate reductase in childhood acute lymphoblastic leukemia Br J Haematol, 2001; 113:746-756 | 2001 |
Omura-Minamisawa M, Diccianni MB, Batova, Chang RC, Bridgeman LJ, Yu J, de Wit E, Kung FH, Pullen J, Camitta B, Yu AL: In vitro sensitivity of T-cell lymphoblastic leukemia to UCN-01 (7-Hydroxystaurosporine) is dependent on p16 protein status: A Pediatric Oncology Group study Cancer Res, 2000; 60:6573-6576 | 2000 |
Harris MB, Shuster JJ, Pullen J, Borowitz MJ, Carroll AJ, Behm FG, Camitta BM, Land VJ: Treatment of children with early pre-B and pre-B acute lymphocytic leukemia with antimetabolite-based intensification regimens: A Pediatric Oncology Group study Leukemia, 2000; 14:1570-1576 | 2000 |
Schneider NT, Carroll AJ, Shuster JJ, Pullen J, Link MP, Borowitz MJ, Camitta BM, Katz JA, Amylon MD: New recurring cytogenetic abnormalities and association of blast cell karyotypes with prognosis in childhood T-cell acute lymphoblastic leukemia. A Pediatric Oncology Group report of 343 cases Blood, 2000; 96:2543-2549 | 2000 |
Arico M, Valsecchi MG, Camitta B, Schrappe M, Chessells J, Baruchen A, Gaynon P, Silverman L, Janka-Schaub G, Kamps W, Pui C-H, Masera G, Conter V, Riehm H, Heerema N, Sallan S, Auclerc MF, Pullen J, Shuster J, Carroll A, Raimondi S, Richards S: Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. International Leukemia Working Group New Engl J Med, 2000; 342: 998-1006 | 2000 |
Kaleem Z, Shuster JJ, Carroll AJ, Borowitz MJ, Pullen DJ, Camitta BM, Zutter MM, Watson MS: Acute lymphoblastic leukemia with an unusual t(8;14)(q11.2;q32): A Pediatric Oncology Group study Leukemia, 2000; 14:238-240 | 2000 |
Omura-Minamisawa M, Dicciana MB, Batova A, Chang R, Bridgeman LJ, Yu J, Pullen J, Bowman WP, Yu A: Universal inactivation of both p16 and p15 but not downstream components is an essential event in the pathogenesis of T-cell acute lymphoblastic leukemia Clin Cancer Res, 2000; 6:1219-1228 | 2000 |
Laver BH, Barredo JC, Amylon M, Schwenn M, Kurtzberg J, Camitta BM, Pullen J, Link MP, Borowitz B, Ravindranath Y, Murphy SB, Shuster J: Effects of cranial radiation in children with high risk T-cell acute lymphoblastic leukemia: A Pediatric Oncology Group Report Leukemia, 2000; 14:369-373 | 2000 |
Pollock B, DeBaun M, Camitta B, Shuster J, Ravindranath Y, Pullen J, Land VJ, Mahoney D, Lauer S, Murphy SB: Ethnic differences in the survival of childhood B-precursor acute lymphoblastic leukemia: A Pediatric Oncology Group study J Clin Oncol, 2000; 18:813-823 | 2000 |
Maloney KW, Shuster JJ, Murphy S, Pullen J, Camitta BM: Long term results of treatment studies for childhood acute lymphoblastic leukemia: Pediatric Oncology Group studies from 1986-1994 Leukemia, 2000; 14:2276-2285 | 2000 |
Batova A, Diccianni MB, Yu J, Bridgeman L, Pullen J, Amylon MJ, Yu AL Use of alanosine as a methylthioadenosine phosphorylase-selective therapy for T-cell acute lymphoblastic leukemia in vitro. Cancer Research. 1999; 59:1492-1497 | 1999 |
Pullen J, Shuster JJ, Link M, Borowitz M, Amylon M, Carroll D, Land V, Look AT, McIntyre B, Camitta B Significance of commonly used prognostic factors differs for children with T-cell acute lymphocytic leukemia (ALL), as compared to those with B-precursor ALL. Leukemia. 1999; 13:1696-1707 | 1999 |
Navid F, Mosijczuk AD, Head DR, Borowitz MJ, Carroll AJ, Brandt MJ, Link MP, Rozans MK, Thomas GA, Schwenn MR, Shields DJ, Vietti TJ, Pullen DJ Acute lymphoblastic leukemia with the (8;14)(q24;q32) translocation and FAB L3 morphology associated with a B-precursor immunophenotype: The Pediatric Oncology Group experience. Leukemia. 1999;13:135-141 | 1999 |
Amylon MD, Shuster J, Pullen J, Berard C, Link MP, Wharam M, Katz J, Yu A, Laver J, Ravindranath Y, Jirtzbert J, Desai S, Camitta , Muphy SB Intensive high dose asparaginase consolidation improves survival for pediatric patients with T-cell acute lymphoblastic leukemia and advanced stage lymphoblastc lymphoma: Pediatric Oncology Group Study 8704 Leukemia. 1999;13:335-342 | 1999 |
Shuster JJ, Camitta BM, Pullen J, Borowitz MJ, Carroll AJ, Look AT, Mahoney DH, Lauer SJ, Land VJ Identiication of newly diagnosed children with acute lymphocytic leukemia at high risk for relapse. Cancer Research Therapy and Control. 1999;9:101-107 | 1999 |
Rubnitz JE, Camitta VM, Mahmoud H, Raimondi SC, Carroll AJ Borowitz MJ, Shister JJ, Link MP, Pullen DJ, Downing JR Behm FG, Pui C-H Childhood acute lymphoblastic leukemia with the MLL-ENL fusion and t(11;19)(q23;p13.3). Journal of Clinical Oncology. 1999;17:191-196 | 1999 |
Borowitz MJ, Rubnitz J, Nash M, Pullen DJ, Camitta B Surface antigen phenotype can predict TEL-AML1 rearrangement in childhood B-precursor ALL. A Pediatric Oncology Group study. Leukemia. 1998;12:1764-1770 | 1998 |
Whitehead VM, Buchich M-J, Lauer SJ, Mahoney D, Shuster JJ, Payment C, Cock A, Adabutu JJ, Bowen T, Kamen BA, Ravindranath Y, Emami A, Look AT, Beardsley GP, Pullen DJ, Camitta BM Accumulation of methotrexate polyglutamates, ploidy and trisomy of chromosomes 4 and 10 in lymphoblasts from children with B-progenitor cell acute lymphoblastic leukemia: A Pediatric Oncology Group study. Leukemia and Lymphoma. 1998;31:507-519 | 1998 |
Lauer SJ, Camitta BM, Leventhal BG, Mahoney D, Shuster JJ, Kiefer G, Pullen J, Steuber CP, Carroll AJ, Kamen B Intensive alternating drug pairs for treatment of infant acute lymphoblastic leukemia. A Pediatric Oncology Group study. J Pediat Hematol/Oncol. 1998;20(3):229-233 | 1998 |
Zhang L, Taub JW, Williams M, Wong SC, Hukku B, Pullen J, Ravindranath Y, Matherly L Reduced folate carrier gene expression in chlidhood acute lymphoblastic leukemia: Relationship to immunophenotype and ploidy. Clin Ca Research. 1998;4:2169-2177 | 1998 |
Shuster JJ, Wacker P, Pullen J, Humbert J, Land VJ, Mahoney DJ, Lauer S, Look AT, Borowitz MJ, Carroll AJ, Camitta BM Prognostic significance of gender in childhood B-precursor acute lymphoblastic leukemia: A Pediatric Oncology Group study. J Clin Oncol, 1998;16(8):2854-2863 | 1998 |
Harris MB, Shuster JJ, Pullen DJ, Borowitz MJ, Carroll AJ, Behm FG, Land VJ Consolidation therapy with anti-metabolite based therapy in standard risk acute lymphocytic leukemia of childhood: A Pediatric Oncology group study. J Clin Oncol, 1998;16(8):2840-2847 | 1998 |
112. Hunger SP, Fall MZ, Camitta BM, Carroll AJ, Link MP, Lauer SJ, Mahoney DH, Pullen DJ, Shuster JJ, Cleary ML Detection of minimal residual disease by amplification of E2A-PBX1 chimeric transcripts at end of consolidation is not predictive of treatment outcome in childhood acute lymphoblastic leukemias with a t(1;19)(q23;p13): A Pediatric Oncology Group study. Blood. 1998;91:1021-1028 | 1998 |
Geiser PW, Chang MN, Rao PV, Shuster JJ, Pullen J Modeling cure rates using the Compertz model with covariate information. Statist Med. 1998;17:831-839 | 1998 |
Whitehead VM, Vuchich M-J, Cooley L, Lauer SJ, Mahoney DH, Shuster JJ, Payment C, Bernstein ML, Akabutu JJ, Bower T, Kamen BA, Watson MS, Look AT, Pullen DJ, Camitta B Translocations involving chromosome 12p11-13, methotrexate metabolism and outcome in childhood B-lineage acute lymphoblastic leukemia. Clin Cancer Res. 1998;4:183-188 | 1998 |
Alvarado CS, Austin GE, Borowitz MJ, Shuster JJ, Carroll AJ, Austin ED, Zhou M, Zaki SR, Pullen J Myeloperoxidase gene expression in infant leukemia: A Pediatric Oncology Group study. Leukemia and Lymphoma. 1998;29:145-160 | 1998 |
Diccianni MB, Batova A, Yu J, Vu T, Pullen J, Amylon M, Pollock B, Yu A Shortened survival after relapse in T cell acute lymphoblastic leukemia for patients with p16/p15 deletions. Leukemia Research. 1997;21(6):549-558 | 1997 |
Batova A, Diccianni MB, Yu JC, Norori T, Link MP, Pullen J, Yu AL Frequent and selective methylation of p15 in addition to p16 deletion in T-cell ALL. Cancer Research. 1997;57:832-836 | 1997 |
Maloney KW, Rubnitz JE, Cleary ML, Frankel LW, Hakami N, Link MP, Pullen DJ, Hunger SP Lack of ETV6 (TEL) gene rearrangements of p16INK4A/p15INK4B homozygous gene deletions in infant acute lymphoblastic leukemia. Leukemia. 1997;11:979-983 | 1997 |
Matherly LH, Taub JW, Wong SC, Simpson P, Ekizian R, Buck S, Amylon M, Pullen J, Camitta B, Ravindranath Y Increased frequency of heterogeneous expression of elevated dihydrofolate reductase in T-cell versus B-precursor acute lymphocytic leukemia in children. Blood. 1997;90(2):578-589 | 1997 |
Borowitz MJ, Shuster J, Carroll AJ, Look AT, Camitta B, Mahoney D, Lauer SJ, Pullen DJ: Prognostic significance of fluorescence intensity of surface marker expression in childhood B-precursor ALL. A Pediatric Oncology Group study. Blood. 1997; 89(11):3960-3966 | 1997 |
Rubnitz JE, Shuster JJ, Land VJ, Link MP, Pullen J, Camitta BM, Pui C-H, Downing JR, Behm FG Case-control study suggests a favorable impact of TEL rearrangement in patients with B-lineage acute lymphoblastic leukemia treated with antimetabolite-based therapy: A Pediaric Oncology Group study. Blood. 1997;89(4):1143-1146 | 1997 |
Camitta BM, Pullen J, Winick N, Murphy S Biology and treatment of acute lymphocytic leukemia in children. Seminars in Oncology. 1997;24(1):83-91 | 1997 |
Frankel LS, Ochs J, Shuster JJ, Dubowy R, Bowman WP, Hockenberry-Eaton M, Borowitz M, Carroll AJ, Steuber CP, Pullen DJ Therapeutic trial for infant acute lymphoblastic leukemia: The Pediatric Oncology Group experience (POG 8493). J Pediatr Hematol/Onco. 1997; 19(1);35-42 | 1997 |
Graham ML, Shuster JJ, Kamen BA, Land VJ, Borowitz MJ, Camitta B, Cheo DL, Harrison MP, Leventhal BG, Pinkel DP, Pullen DJ, Steuber P, Whitehead VM Changes in red blood cell methotrexate pharmacology and their impact on outcome when cytarabine is infused with methotrexate in the treatment of acute lymphocytic leukemia in children: A Pediatric Oncology Group study. Clin Cancer Res. 1996;2:331-337 | 1996 |
Smith M, Arthur D, Camitta B, Carroll AJ, Crist W, Gaynon P, Gelber R, Heerema N, Korn E, Link M, Murphy S, Pui C-H, Pullen J, Reaman G, Sallan SE, Sather H, Shuster J, Simon R, Trigg M, Tubergen D, Uckun F, Underleider R A uniform approach to risk-classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol. 1996;14(1):18-24 | 1996 |
Martin PL, Look AT, Schnell S, Harris MB, Pullen J, Shuster JJ, Carroll AJ, Pettenati MJ, Rao N Comparison of fluorescence in situ hybridization, cytogenetic analysis and DNA index analysis to detect chromosomes 4 and 10 aneuploidy in pediatric acute lymphoblastic leukemia A Pediatric Oncology Group study. J Pediatr Hematol/Oncol. 1996;18(2):113-121 | 1996 |
Bowman WP, Shuster JJ, Cook B, Griffin T, Behm F, Pullen J, Link M, Head D, Carroll A, Berard C, Murphy S Improved survival for children with B-cell acute lymphoblastic leukemia and stage IV small noncleaved cell lymphoma: A Pediatric Oncology Group study. J Clin Oncol. 1996;14(4):1252-1261 | 1996 |
Mahmoud HH, Schwartz C, Shuster J, Pui CH, Behm F, Amylon M, Raimondi S, Borowitz M, Link M, Pullen J, Camitta B, Hakami N, Crist W, Carroll A The (11;19) translocation is associated with poor outcome in infants with acute lymphoblastic leukemia. A collaborative study of the POG and SJCRH. Med Ped Oncol. 1994;23:199-204 | 1994 |
Land VJ, Shuster JJ, Crist WM, Ravindranath Y, Harris MB, Krance RA, Pinkel D, Pullen DJ: Comparison of two schedules of intermediate-dose methotrexate and cytarabine consolidation therapy for childhood B-precursor cell acute lymphoblastic leukemia: A Pediatric Oncology Group study. J Clin Oncol. 1994;12:1939-¬1949 | 1994 |
Rubnitz JE, Link MP, Shuster JJ, Carroll AJ, Hakami N, Frankel LS, Pullen DJ, Cleary ML Frequency and prognostic significance of HRX rearrangements in infant acute lymphoblastic leukemia: A Pediatric Oncology Group study. Blood, 1994;84:570¬573 | 1994 |
Downing JR, Head DR, Raimondi SC, Carroll AJ, Curcio-Brint AM, Motroni TA, Hulshof MG, Pullen DJ, Domer PH The der(11) encoded MLL-AF-4 fusion transcript is consistently detected in t(4;11)(q21;q23) containing acute lymphoblastic leukemia. Blood. 1994;83:330-335 | 1994 |
Smith JC, Megason GC, Iyer RV, Andrew ME, Pullen DJ Clinical characteristics of children with hereditary hemolytic anemias and aplastic crisis: A 7 year review. Southern Med J. 1994;87(7):702-708 | 1994 |
Pettenati MJ, Rao N, Wofford M, Shuster JJ, Pullen DJ, Steuber CP, Carroll AJ Presenting characteristics of trisomy 8 as the primary cytogenetic abnormality associated with childhood acute lymphoblastic leukemia -A Pediatric Oncology Group study. Cancer Genet Cytogenet. 1994;75:6-10 | 1994 |
Smith M speaking for Arthur D, Camitta B, Crist W, Gaynon P, Gelber R, Heerema N, Korn E, Link M, Murphy S, Pui C-H, Pullen J, Reaman G, Sallan S, Sather H, Shuster J, Simon R, Trigg M, Tubergen D, Uckun F, Ungerleider R Towards a more uniform approach to risk-classification and treatment assignment for children with acute lymphoblastic leukemia. Presented, May 1994, Dallas TX. Amer Soc Clin Oncol.1994; Educational Book, pgs 124-130 | 1994 |
Pui C-H, Carroll AJ, Raimondi SC, Shuster JJ, Crist WM, Pullen DJ Childhood ALL with the t(4;11)(q21;q23):An update. Blood. 1994;83(8):2384-2385 | 1994 |
Duffner P, Burger P, Cohen M, Sanford R, Krischer J, Elterman R, Aronin P, Pullen J, Horowitz M, Parent A, Kun L Desmoplastic infantile gangliogliomas: An approach to therapy. Neurosurgery. 1994;34(4):583-589 | 1994 |
Kato GJ, Quddus FF, Leventhal BG, Shuster JJ, Boyett J, Behm FG, Pullen DJ, Borowitz JM, Whitehead VM, Crist WM Glucocorticoid receptor content of leukemic blasts is a favorable prognostic factor in childhood acute lymphoblastic leukemia. Blood. 1993;82(8):2304-2309 | 1993 |
Watson MS, Carroll AJ, Shuster JJ, Steuber CP, Borowitz MJ, Behm FG, Pullen DJ, Land VJ Trisomy 21 in childhood acute lymphoblastic leukemia (ALL). A Pediatric Oncology Group study. Blood. 1993;82(10):3098-3102 | 1993 |
Shuster JJ, Carroll AJ, Look TA, Pui CH, Land VJ, Jackson J, Pullen DJ, Steuber CP, Crist WM Management of cytogenetic data in multi-center leukemia trials. Computer Methods and Programs in Biomedicine. 1993;40:269-277, 1993 | 1993 |
Koehler M, Behm F, Shuster J, Crist W, Borowitz M, Look AT, Head D, Carroll AJ, Land V, Steuber P, Pullen DJ Transitional pre-B-cell acute lymphoblastic leukemia of childhood is associated with prognostically favorable clinical features and an excellent outcome. A Pediatric Oncology Group study. Leukemia. 1993;7(12):2064-2068 | 1993 |
Borowitz MJ, Hunger SP, Carroll AJ, Shuster JJ, Pullen DJ, Steuber CP, Cleary ML Predictability of the t(1;19)(q23;q13) from surface antigen phenotype: Implications for screening cases of childhood ALL for molecular analysis. A Pediatric Oncology Group study. Blood. 1993;82(4):1086-1091 | 1993 |
Pui C-H, Raimondi SC, Borowitz MJ, Land VJ, Behm FG, Pullen DJ, Hancock ML, Shuster JJ, Steuber CP, Crist WM, Civin CI, Carroll AJ Acute lymphoblastic leukemia in children with Down Syndrome. J Clin Oncol. 1993;11:1361-1367 | 1993 |
Lauer SJ, Camitta B, Leventhal B, Mahoney D, Shuster JJ, Adair S, Casper J, Civin C, Graham M, Kiefer G, Pullen J, Steuber P, Kamen B Intensive alternating drug pairs for treatment of high risk childhood acute lymphoblastic leukemia: A Pediatric Oncology Group pilot study. Cancer. 1993;71:2854-2861 | 1993 |
Pullen J, Boyett J, Shuster J, Crist W, Land V, Frankel L, Iyer R, Backstrom L, van Eys J, Harris M, Ravindranath Y, Sullivan M Extended triple intrathecal chemotherapy trial for prevention of CNS relapse in good-risk and poor-risk patients with B-progenitor acute lymphoblastic leukemia: A Pediatric Oncology Group study. J Clin Oncol, 1993;11(5):839-849 | 1993 |
Bash RO, Crist WM, Shuster JJ, Link MP, Amylon M, Pullen J, Buchanan GR, Smith RG, Baer R Clinical features and outcome of T-cell acute lymphoblastic leukemia in childhood with respect to alteration at the TAL1 locus, A Pediatric Oncology Group study. Blood. 1993;81 (8):2110-2117 | 1993 |
Graham ML, Shuster JJ, Kamen BA, Cheo DL, Harrison MP, Leventhal BG, Pullen DJ, Whitehead VM Red blood cell methotrexate and folate levels in children with acute lymphoblastic leukemia undergoing therapy: a Pediatric Oncology Group pilot study. Cancer Chemother Pharmacol, 1992; 31:271-222 | 1992 |
Whitehead VM, Vuchich MJ, Lauer S, Mahoney D, Carroll AJ, Shuster JJ, Esseltine DL, Payment C, Look TA, Akabutu J, Bowen T, Taylor LT, Camitta B, Pullen DJ Accumulation of high levels of methotrexate polyglutamates in lymphoblasts from children with hyperdiploid (>50 chromosomes) B-lineage acute lymphoblastic leukemia: A Pediatric Oncology Group study. Blood. 1992;80(5):1316-1323 | 1992 |
Falletta JM, Shuster JJ, Crist WM, Pullen DJ, Borowitz MJ, Wharam M, Petterson R, Foreman E, Vietti TJ Different patterns of relapse associated with three intensive treatment regimens for pediatric E-rosette positive T-cell leukemia: A Pediatric Oncology Group study. Leukemia. 1992;6(6):541-546 | 1992 |
Krance RA, Raimondi SC, Dubowy R, Estrada J, Borowitz M, Behm F, Land VJ, Pullen J, Carroll AJ t(12;17)(p13;q21) in early pre-B acute lymphoid leukemia. Leukemia. 1992;6(4):251-255 | 1992 |
Abshire TC, Buchanan GR, Jackson JF, Shuster JJ, Brock B, Head D, Behm F, Crist WM, Link MP, Borowitz M, Pullen DJ Serial morphologic, immunologic and cytogenetic studies in children with acute lymphoblastic leukemia: A Pediatric Oncology Group study. Leukemia. 1992;6:357-362 | 1992 |
Mahmoud H, Carroll AJ, Behm F, Raimondi S, Shuster J, Borowitz M, Land V, Pullen DJ, Vietti TJ, Crist W The non-random dic(9;12) translocation is exclusively associated with the B-progenitor phenotype and confers an excellent prognosis. Leukemia. 1992;6(7):703-707 | 1992 |
Crist W, Shuster J, Look T, Borowitz M, Behm F, Bowman P, Frankel L, Pullen J, Steuber P, Amylon M, Link M, Land V Current results of immunophenotype-, age¬and leukocyte-based therapy for children with acute lymphoblastic leukemia. A Pediatric Oncology Group study. (Presented at Fifth International Symposium on Therapy of Acute Leukemias, Rome, Italy, November 1-6, 1991.) Leukemia 6:162-167, 1992 Leukemia. 2991;6:162-167 | 1992 |
Harris MB, Shuster JJ, Carroll A, Look AT, Borowitz MJ, Crist WM, Nitschke R, Pullen J, Steuber CP, Land VF Trisomy of leukemic cell chromosomes 4 and 10 identifies children with B-progenitor cell acute lymphoblastic leukemia with a very low risk of treatment failure. A Pediatric Oncology Group study. Blood. 2991;79(12):3316-3324 | 1992 |
Watson MS, Land VJ, Carroll AJ, Pullen J, Borowitz MJ, Link MP, Amylon M, Behm FG t(2;14)(p13;q32): A recurring abnormality in lymphocytic leukemia. Cancer Genet Cytogenet. 1992;58:121-124 | 1992 |
Trueworthy R, Shuster J, Look T, Crist W, Borowitz M, Carroll A, Frankel L, Harris M, Wagner H, Haggard M, Misijczuk A, Pullen J, Steuber P, Land V Ploidy of lymphoblasts is the strongest predictor of treatment outcome in B-progenitor cell acute lymphoblastic leukemia of childhood: A Pediatric Oncology Group study. J Clin Oncol. 1992;10(4):606-613 | 1992 |
Sullivan M, Brecher M, Ramirez I, Ragab A, Hvizdala E, Pullen J, Shuster J, Berard C High-dose cyclophosphamide --high-dose methotrexate with coordinated intrathecal therapy for advanced non-lymphoblastic non-Hodgkin's lymphoma of childhood: Results of a POG study. Am J Ped Hem Onc. 1991;13(3):288-295 | 1991 |
Krance RA, Newman EM, Ravindranath Y, Harris MB, Brecher M, Wimmer R, Shuster JJ, Land VJ, Pullen J, Crist W, Pinkel E A pilot study of intermediate-dose methotrexate and cytosine arabinoside, "spread-out" or "up-front" in continuation therapy for chldhood non-T, non-B acute lymphoblastic leukemia. A Pediatric Oncology Group study. Cancer. 1991;67(3):550-556 | 1991 |
Cerezo L, Shuster JJ, Pullen J, Brock B, Borowitz MJ, Falletta JM, Crist WM, Head DR Laboratory correlates and prognostic significance of granular acute lymphoblastic leukemia in children. A Pediatric Oncology Group study. Am J Clin Pathol. 1991;95(4):526-531 | 1991 |
Russo C, Carroll A, Kohler S, Borowitz M, Amylon M, Homans A, Kedar A, Shuster J, Land V, Crist W, Pullen J, Link M The Philadelphia chromosome and monosomy 7 in childhood acute lymphoblastic leukemia. A Pediatric Oncology Group study. Blood. 1991;77(5):1050-1056 | 1991 |
Pui C-H, Frankel LS, Carroll AJ, Raimondi SC, Shuster JJ, Head DR, Crist WM, Land VJ, Pullen DJ, Steuber CP, Behm FG, Borowitz MJ Clinical characteristics and treatment outcome of childhood acute lymphoblastic leukemia with t(4;11)(q21;q23). A collaborative study of 40 cases. Blood. 1991;77(3):440-447 | 1991 |
Pui C-H, Carroll AJ, Head D, Raimondi SC, Shuster JJ, Crist WM, Link MP, Borowitz MJ, Behm FG, Land VJ, Nash MG, Pullen DJ, Look AT Near-triploid and near tetraploid acute lymphoblastic leukemia of childhood. Blood. 1991;76(3):590-596 | 1991 |
Carroll AJ, Crist WM, Link MP, Amylon MD, Pullen DJ, Ragab AH, Buchanan GR, Wimmer RS, Vietti TJ The t(1;14)(p34;q11) is nonrandom and restricted to T-cell acute lymphoblastic leukemia: A Pediatric Oncology Group study. Blood. 1990;76(6):1220-1224 | 1990 |
Crist W, Carroll A, Shuster J, Jackson J, Head D, Borowitz M, Behm F, Link M, Steuber P, Ragab A, Hirt A, Brock B, Land V, Pullen J Philadelphia chromosome positive childhood acute lymphoblastic leukemia: Clinical and cytogenetic characteristics and treatment outcome. Blood. 1990;76:489-494 | 1990 |
Borowitz M, Shuster JJ, Civin CI, Carroll AJ, Look AT, Behm FG, Land VJ, Pullen DJ, Crist WM Prognostic significance of CD34 expression in childhood B¬precursor acute lymphocytic leukemia. A Pediatric Oncology Group study. J Clin Oncol. 1990; 8(8):1389-1398 | 1990 |
Crist WM, Carroll AJ, Shuster JJ, Behm FG, Whitehead M, Vietti RJ, Look AT, Mahoney D, Ragab A, Pullen DJ, Land VJ Poor prognosis of children with pre-B acute lymphoblastic leukemia is associated with the t(1;19)(q23;p13). A Pediatric Oncology Group study. Blood. 1990; 76(1):117-112 | 1990 |
Sullivan MP, Pullen J, Crist W, Head D, Cerezo L, Brecher M, Ramirez I, Sabio H, Borowitz M, Shuster J, Murphy S Clinical and biological heterogeneity of childhood B-cell leukemia: Implications for clinical trials. Leukemia. 1990;4(1):6-11 | 1990 |
Jackson JF, Boyett J, Pullen J, Brock B, Patterson R, Land V, Borowitz M, Head D, Crist W Favorable prognosis associated with hyperdiploidy in children with acute lymphocytic leukemia correlates with extra chromosome 6. Cancer. 1990;66(6):1183-1189 | 1990 |
Pui C-H, Carroll AJ, Raimondi SC, Land VJ, Crist WM, Williams DL, Pullen DJ, Borowitz MJ, Behm FG, Look AT Clinical presentation, karyotypic characterization, and treatment outcome of childhood acute lymphoblastic leukemia with a near-haploid and hypodiploid <45 line. Blood. 1990;75(5):1170-1177 | 1990 |
Shuster JJ, Falletta JM, Pullen DJ, Crist WM, Humphrey GB, Dowell BL, Wharam MD, Borowitz M: Prognostic factors in childhood T-cell acute lymphoblastic leukemia. Blood. 1990;75(1):166-173 | 1990 |
Crist W, Boyett J, Jackson J, Vietti T, Borowitz M, Chauvenet A, Winick N, Ragab A, Mahoney D, Head D, Iyer R, Wagner H, Pullen J: Prognostic importance of the pre-B cell immunophenotype and other presenting features in B-lineage childhood lymphocytic leukemia. Blood. 1989;74(4):1252-1259 | 1989 |
van Eys J, Berry D, Crist W, Doering E, Fernbach D, Pullen J, Shuster J Treatment intensity and outcome for children with acute lymphocytic leukemia of standard risk. A Pediatric Oncology Group study. Cancer. 1989;63:1466-1471 | 1989 |
Dubansky AS, Boyett J, Falletta J, Mahoney D, Land V, Pullen J, Buchanan G The rarity of isolated severe thrombocytopenia in acute lymphoblastic leukemia. A Pediatric Oncology Group study. Pediatrics. 1989;84:1068-1071 | 1989 |
van Eys J, Berry D, Crist W, Doering E, Fernbach D, Pullen J, Shuster J, Wharam M A comparison of two regimens for high risk acute lymphocytic leukemia in childhood. A Pediatric Oncology Group study. Cancer. 1989;63(1):23-29 | 1989 |
Crist WM, Shuster JJ, Falletta J, Pullen DJ, Berard CW, Vietti TJ, Alvarado CS, Roper MA, Prasthofer E, Grossi CE Clinical features and outcome in childhood T-cell leukemia-lymphoma according to stage of thymocyte differentiation: A Pediatric Oncology Group study. Blood. 1988;72(6):1891-1897 | 1988 |
Nuss R, Kitchingman G, Cross A, Zipf TF, Antoun GR, Bernstein I, Behm F, Pullen DJ, Crist W, Mirro J, Goorha R T cell gene rearrangements in B-precursor acute lymphoblastic leukemia correlate with age and the stage of B cell differentiation. Leukemia. 1988;2(1):722-727 | 1988 |
Hurwitz CA, Loken MR, Graham ML, Karp JE, Borowitz MF, Pullen DJ, Civin CI Asynchronous antigen expression in B lineage acute lymphoblastic leukemia. Blood. 1988;72(1):299-307 | 1988 |
Crist W, Pullen J, Boyett J, Falletta J, van Eys J, Borowitz M, Jackson J, Dowell B, Russell C, Quddus F, Ragab A, Vietti T Acute lymphoid leukemia in adolescents: Clinical and biologic features predict a poor prognosis - A Pediatric Oncology Group study. J Clin Oncol. 1988; 6:34-43 | 1988 |
Carroll AJ, Raimondi SC, Williams DL, Behm FG, Borowitz M, Castleberry RP, Harris MB, Patterson RB, Pullen DJ, Crist WM tdic (9;12): A nonrandom chromosome abnor¬mality in childhood B-cell precursor acute lymphoblastic leukemia (ALL): A Pediatric Oncology Group study. Blood. 1987;70(6):1962-1965 | 1987 |
Morabito F, Prasthofer EF, Pullen DJ, Mahoney D, Downing JR, Crist WM, Grossi CE Analysis of surface antigen profile, TdT expression, and T cell receptor gene rearrangement for maturational staging of leukemic T cells. A Pediatric Oncology Group study. Leukemia. 1987;1(6):514-517 | 1987 |
Dowell BL, Borowitz MJ, Boyett JM, Pullen DJ, Crist WM, Quddus FF, Russell EC, Falletta JM, Metzgar RS Immunologic and clinicopathologic features of common acute lymphoblastic leukemia antigen-positive childhood T-cell leukemia. A Pediatric Oncology Group study. Cancer, 1987;59:2020-2026 | 1987 |
van Eys J, Berry DM, Crist W, Doering EJ, Fernbach DJ, Pullen J, Shuster J Effect of Trimethoprim/Sulfamethoxazole prophylaxis on outcome of childhood acute lymphocytic leukemia. A Pediatric Oncology Group study. Cancer. 1987;59(1):19-23 | 1987 |
Steinberg MH, Adams JG, Morrison WT, Pullen DJ, Abney R, Ibrahim A, Rieder RF Hemoglobin Mississippi (B44ser-cys): Studies of the Thalassemic phenotype in a mixed heterozygote with B+-Thalassemia. J Clin Inves. 1987; 79:826-832 | 1987 |
van Eys J, Pullen J, Head D, Boyett J, Crist WM, Falletta J, Humphrey GB, Jackson J, Riccardi V, Brock B The French-American-British (FAB) classification of leukemia. The Pediatric Oncology Group experience with lymphocytic leukemia. Cancer, 1986;57(5):1046-1051 | 1986 |
Head DR, Borowitz M, Cerezo L, Craven CM, Brock BL, Boyett JM, Pullen DJ, Crist WM, Falletta J, Humphrey GB Acid phosphatase positivity in childhood acute lymphocytic leukemia. Amer J Clin Pathol. 1986;86(5):650-653 | 1986 |
Crist W, Boyett J, Pullen J, van Eys J, Vietti T Clinical and biologic features predict poor prognosis in acute lymphoid leukemias in children and adolescents. A Pediatric Oncology Group study. Presented at SIOP Workshop, October 7-8, 1985, Rome, Italy. Med Pediatr Oncol. 1986;14:135-139 | 1986 |
Crist W, Pullen J, Boyett J, Falletta J, van Eys J, Borowitz M, Jackson J, Dowell B, Frankel L, Quddus F, Ragab A, Vietti T Clinical and biologic features predict poor prognosis in acute lymphoid leukemias in infants: A Pediatric Oncology Group study. Blood, 1986;67(1):135-140 | 1986 |
Borowitz MJ, Dowell BL, Boyett JM, Pullen DJ, Crist WM, Quddus FF, Falletta JM, Metzgar RS Clinicopathologic aspects of E-rosette negative T cell acute lymphocytic leukemia. A Pediatric Oncology Group study. J Clin Oncol. 1986;4(2):170¬177 | 1986 |
Crist W, Rivera G, Pullen J, Weinstein H The leukemias of childhood. Hematology 1985: Education Program of the American Society of Hematology, pages 48-54 | 1985 |
Quddus FF, Leventhal BG, Boyett JM, Pullen DJ, Crist WM, Borowitz MJ Glucocorticoid receptors in immunologic subtypes of childhood acute lymphocytic leukemia cells: A Pediatric Oncology Group study. Cancer Res. 1985;45:6482-6486 | 1985 |
Borowitz MJ, Dowell BL, Boyett JM, Falletta JM, Pullen DJ, Crist WM, Humphrey GB, Metzgar RS Monoclonal antibody definition of T-cell acute leukemia. A Pediatric Oncology Group study. Blood. 1985;65(4):785-788 | 1985 |
Crist WM, Grossi C, Pullen J, Cooper MD Immunologic markers in childhood acute lymphocytic leukemia. Semin Oncol 12(2):105-121, 1985 | 1985 |
Sullivan MP, Boyett J, Pullen J, Crist W, Doering EJ, Trueworthy R, Hvizdala E, Ruymann R, Steuber CP Pediatric Oncology Group experience with modified LSA2-L2 therapy in 107 children with non-Hodgkin's lymphoma (Burkitt's lymphoma excluded). Cancer. 1985;55(2):323-326 | 1985 |
Humphrey GB, Blackstock R, Falletta JM, Metzgar RS, Richie ER, Pullen DJ, Boyett JM, Shuster JJ, Roper MA, Russell EC, Mahoney DH, Ragab AH An analysis of the presence of Fc receptors on bone marrow lymphoblasts in acute lymphoblastic leukemia. Cancer. 1985;(8):1995-2000 | 1985 |
Cerezo L, Head DR, Pullen J, Humphrey B The prevalence of hand-mirror cells in acute myeloblastic and lymphoblastic leukemia. Amer J Clin Pathol. 1984;81:355-357 | 1984 |
Falletta J, Boyett J, Pullen J, Crist W, Dowell B, Roper M, Humphrey B, Metzgar R, Cooper M, van Eys J Clinical and phenotype features of childhood ALL by race and Spanish origin. Presented International Workshop on the influence of the Environment on Leukemia and Lymphoma Subtypes. Workshop Proceedings, Raven Press, vol 27, pp 191-195, 1984 | 1984 |
Crist W, Boyett J, Roper M, Pullen J, Metzgar R, van Eys J, Ragab A, Starling K, Vietti T, Cooper M Pre-B cell leukemia responds poorly to treatment: A Pediatric Oncology Group study. Blood 63, 1984;2):407-414. Selected for inclusion in Year Book of Cancer, 1985, RC Hickey, GF Saunders, RL Clark and RW Cumley (eds), Year Book Medical Publishers, Inc, Chicago, pp 175-176 | 1984 |
Frankel LS, Wang YM, Shuster J, Nitschke R, Doering EJ, Pullen J High dose methotrexate in the maintenance of remission in acute lymphocytic leukemia: A Pediatric Oncology Group pilot study. J Clin Oncol. 1983;1(12):804-809 | 1983 |
Roper M, Crist WM, Metzgar R, Ragab AH, Smith S, Starling K, Pullen J, Leventhal B, Bartolucci AA, Cooper MD Monoclonal antibody characterization of surface antigens in childhood T-cell lymphoid malignancies. Blood. 1983;61(5):830-837 | 1983 |
Jackson JF, Pullen J, Williams DL, Bowman P, Roper M, Carroll AJ, Vogler L, Crist W, Starling KA, van Eys J 982 Cytogenetics of B-cell lineage acute lymphocytic leukemias of childhood. The Lancet II. 1982;(8311):1334 | 1982 |
Komp DM, Fernandez CH, Falletta JM, Ragab AH, Humphrey GB, Pullen DJ, Moon T, Shuster J CNS prophylaxis in acute lymphoblastic leukemia - comparison of two methods. A Southwest Oncology Group study. Cancer. 1982;50:1031-1036 | 1982 |
Pullen DJ, Sullivan MP, Falletta JM, Boyett JM, Humphrey GB, Starling KA, Land VJ, Dyment PG, Vats T, Duncan MH Modified LSA2-L2 treatment in 53 children with E-rosette positive T-cell leukemia: Results and prognostic factors. (A Pediatric Oncology Group study.) Blood. 1982;60:1159-1168 | 1982 |
Sullivan MP, Ramirez I, Pullen J, Moore T, Doering EJ, Falletta JM, Trueworthy R, Chen T Use of Cytosar in pediatric non-Hodgkin's lymphoma. Proceedings Upjohn Cytosar Symposium, December, 1981 | 1981 |
Nitschke R, Starling K, Lui VKS, Pullen J Doxorubicin and cisplatin therapy in children with neuroblastoma resistant to conventional therapy: A Southwest Oncology Group study. Cancer Treat Rep. 1981;65:1105-1108 | 1981 |
Pullen DJ, Falletta JM, Crist WM, Vogler LB, Dowell B, Humphrey GB, Blackstock R, van Eys J, Cooper MD, Metzgar RS, Meydrech EF Southwest Oncology Group experience with immunological phenotyping in acute lymphocytic leukemia of childhood. Presented NCI conference: Cell Markers in Acute Leukemia, 3/5/80. Bethesda, Maryland. Cancer Res. 1981;41:4802-4809 | 1981 |
Vogler LB, Crist WM, Sarrif AM, Pullen DJ, Bartolucci AA, Falletta JM, Dowell B, Humphrey GB, Blackstock R, van Eys J, Metzgar RS, Cooper MD 1981 An analysis of clinical and laboratory features of acute lymphocytic leukemias with emphasis on 35 children with pre-B cell leukemia. Blood. 1981;58(1):135-140 | 1981 |
Berry DH, Fernbach D, Herson J, Pullen J, Sullivan M, Vietti T Comparison of prednisone, vincristine, methotrexate and 6-mercaptopurine vs 6-mercaptopurine and prednisone maintenance therapy in childhood acute leukemia. A Southwest Oncology Group Study. Cancer. 1980;46:1098-1103 | 1980 |
Miale T, Hvizdala E, Ragab A, Pullen J, O'Brien P, McMillan C Cyclocytidine in the treatment of refractory acute childhood leukemia: A Southwest Oncology Group phase I-II study. Cancer Treat Re. 1979;63:1913-1915 | 1979 |
Herson J, Starling KA, Dyment PC, Humphrey GB, Pullen J, Vats T Vincristine and prednisone versus vincristine, L-asparaginase and prednisone for second remission induction of acute lymphocytic leukemia. Med Pediatr Oncol. 1979;6:317-323 | 1979 |
Trueworthy RC, Sutow WW, Pullen J, Komp D, Berry DH Repeated use of L-Asparaginase in multi-drug therapy of childhood leukemia. Med Pediatr Oncol. 1978;4:91-97 | 1978 |
Lane DM, George SL, Komp D, Lonsdale D, Pullen J, Ragab A, Starling KA Effects of continuous or discontinuous maintenance therapy on subsequent remission maintenance in childhood leukemia. Cancer. 1977;40:2005-2009 | 1977 |
Cangir A, Morgan SK, Land V, Pullen J, Starling KA, Nitschke R Combination chemotherapy with adriamycin and dimethyl triazeno imidazole carboximide (DTIC) in children with metastatic solid tumors. Med Pediat Oncol. 1976;2:183-190 | 1976 |
Sutow WW, Thomas D, Steuber PC, Pullen J, Vats T, Bryan JH, Morgan SK Study of cytosine arabinoside synchronization plus vincristine, prednisone and L¬asparaginase for remission induction in advanced acute leukemia in childhood. Cancer Treat Rep. 1976;60(5):591-594 | 1976 |
Pullen DJ, Dyment PG, Humphrey GB, Lane DM, Ragab AH Combined chemotherapy in childhood rhabdomyosarcoma. Cancer Chemother Rep. 1975;59(2):359-365 | 1975 |
Berry DH, Pullen J, George S, Vietti T, Sullivan MP, Fernbach D Comparison of prednisolone, vincristine, methotrexate and 6-mercaptopurine (POMP) vs. vincristine and prednisone induction therapy in childhood acute leukemia. Cancer. 1975;36:98-102 | 1975 |
Pullen DJ, Smith R Newborn hematologic problems. J Miss State Med Assoc. 1970;11:543-553 | 1970 |
Pullen DJ The fluorescent demonstration of anti-platelet antibodies in platelets and megakaryocytes. Tulane Faculty Bulletin, 1961 | 1961 |
Abstracts | |
Winick N, Martin P, Devidas M, Shuster J, Borowitz MJ, Bowman P, Larsen E, Pullen J, Hunger SP, Carroll WL, Camitta B A delayed intensification enhances continuous complete remission for patients with B-ALL when combined with intravenous methotrexate. Children's Oncology Group study POG 9904/9905 Pediatr Blood Cancer 2017; 64 (S3):0-018 | 2017 |
Sitthi-Amorn J, Herrington B, Megason G, Pullen J, Gordon C, Hogan S, Koganti T, Hicks C Molecular basis of minimal residual disease in subtypes of pediatric B cell acute lymphoblastic leukemia Blood 2013; 122(21):1390 | 2013 |
Chen I, Harvey R, Mullighan CG, Loh ML, Devidas M, Borowitz MJ, Tasian SK, Payne-Turner D, Wharton W, Pullen J, Carroll AJ, Carroll WL, Camitta BM, Hunger S, Winick NJ, Willman CL Relationship of CRLF2 expression and outcome in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL): A report from the Children's Oncology Group J Clin Oncol 29 (abst 9505), 2011 (Platform presentation, ASCO 2011) | 2011 |
Martin PL, Winick N, Devidas M, Shuster J, Borowitz M, Willman C, Bowman WP, Larsen E, Pullen J, Hunger SP, Carroll W, Camitta BM: Outcomes with 4 hr vs 24 hr IV methotrexate infusions during intensification therapy for childhood ALL: POG 9904/9905. A Chlidren's Oncology Group study Pediatric Blood and Cancer, 2008; 51:21 (Platform presentation, American Society of Pediatric Hematology/Oncology) | 2008 |
Borowitz MJ, Devidas M, Hunger SP, Carroll WL, Linda S, Pullen DJ, Viswanatha D, Willman CL, Winick N, Camitta BM: Prognostic significance of end consolidation minimal residual disease in childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group Journal of Clinical Oncology, 2008; 26:539a (Platform presentation, American Society of Clinical Oncology) | 2008 |
Winick N, Martin P, Devidas M, Shuster J, Borowitz MJ, Bowman P, Larsen E, Pullen J, Hunger SP, Carroll WL, Camitta B. Delayed intensification enhances event-free survival of children with B-precursor acute lymphoblastic leukemia who received intensification therapy with six courses of intravenous methotrexate: POG 9904/9905: A Children's Oncology Group study Blood, 2007; 110:583 (Platform presentation, American Society of Hematology) | 2007 |
Winick N, Borowitz MJ, Devidas M, Martin PL, Pullen J, Hunger SP, Carroll WL, Camitta B: Changes in the delivery of standard chemotherapeutic agents during induction affect early measure of minimal residual disease: POG 9900 for patients with B-precursor low and standard risk ALL Blood, 2006; 108:643a(Poster presentation, ASH) | 2006 |
Borowitz MJ, Devidas M, Bowman WP, Carroll WL, Chen I, Harvey R, Hunger S, Martin PJ, Pullen J, Viswanatha D, Willman CL, Winick N, Camitta B: Prognostic significance of minimal residual disease in childhood B-precursor ALL and its relation to other risk factors. A Children’s Oncology Group study Blood, 2006; 108:69a(Platform presentation, ASH) | 2006 |
Rubnitz J, Wichlan D, Devidas M, Shuster S, Kurtzberg J. Bell B, Hunger S, Chauvenet A, Pui C-H, Camitta B, Pullen J: Prospective analysis of TEL and MLL gene rearrangements in childhood acute lymphoblastic leukemia: a Children’s Oncology Group study Blood. 2006; 108:68a(Platform presentation, ASH) | 2006 |
MJ, Devidas M, Bowman WP, Larsen E, Pullen J, Camitta B: Prognostic significance of minimal residual disease in children with high risk acute lymphoblastic leukemia. A Children’s Oncology Group study Blood , 2005;160:29a(Platform presentation, ASH) | 2005 |
Mehta PA, Davies SM, Kumar A, Devidas M, Lee S, Wilke T, Elliott J, Villneuva J, Pullen J, Zewge Y, Filipovich AH: Perforin polymorphism A91V and susceptibility to childhood acute lymphoblastic leukemia Blood, 2005; 160:1453(Poster presentation, ASH) | 2005 |
Rice MA, Bell BA, Chauvenet A, Kurtzbert J, Abish SB, Pullen J, Devidas M, Camitta BM: Thrombotic and hemorrhagic events for patients on Pediatric Oncology Group protocols 9201, 9605, 9406 Blood, 2005; 106:880(Poster presentation, ASH) | 2005 |
Bell BA, Abish SB, Chauvenet A, Kurtzberg J, Pullen J, Devidas M, Shuster J, Camitta BM: A report of the event free survival for children with newly diagnosed standard risk acute lymphoblastic leukemia treated on Pediatric Oncology Group protocol 9605 Blood, 2005; 106:257a(Poster presentation, ASH) | 2005 |
Chauvenet A, Martin P, Bell B, Kurtzbert J, Pullen J, Shuster J, Devidas M, Linda J, Camitta B: Anti-metabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: Pediatric Oncology Group Study 9201 Presented at annual meeting of Pediatric Academy of Sciences, May 2005, Washington DC | 2005 |
Rodes S, Bell BA, Abish SB, Pullen J, Chauvenet A, Kurtzberg J, Devidas M, Shuster J, Camitta BM: A report of the event free survival and neurotoxixicity for children with newly diagnosed standard risk acute lymphoblastic leukemia on Pediatric Oncology Group protocol 9405 Blood, 2005; 106:882(Poster presentation, ASH) | 2005 |
Borowitz MJ, Pullen DJ, Winick N, Martin P, Bowman WP, Camitta B: Comparison of diagnostic and relapse flow cytometry phenotypes in childhood acute lymphoblastic leukemia: Implications for residual disease detection Blood, 2004; 104:310a(Presented, ASH) | 2004 |
Schultz KR, Pullen J, Sather H, Shuster J, Borowitz M, Heerema N, Carroll AJ, Gaynon P, Camitta B: Biology-driven classificaion of childhood acute lymphoblastic leukemia: A combined analysis of prognostic markers from the Pediatric Oncology Group and Children’s Cancer Group Blood, 2004; 104:151a(Presented, ASH) | 2004 |
Angiolillo AL, Davenport V, Krailo M, Jakacki R, Pullen J, Bonilla MA, Reaman G, Cairo MS: Preliminary results of pre and post thrombopoietin prior to and after ICE chemotherapy iosfamide/carboplatin/ etoposide) in children with solid tumors: A Children’s Oncology Group report Proc Am S Clinical Oncol, 2003; 22:175(Presented, ASPHO) | 2003 |
Heerema NA, Shuster J, Biegel J, Camitta B, Cooley LD, Hirsch B, Magenis HE, Patil S, Pettenati MJ, Pullen J, Raimondi SC, Rao K, Schneider NR, Roulston D, Sanger W, Sather HN, Sutcliff MJ, van Tuinen P, Watson MS, Carroll AJ: Pattern of extra chromosomes in pediatric hyperdiploid (50 to 67 chromosomes) acute lymphoblastic leukemia (ALL) is modal number (mn) dependent Blood, 2002; 100:308a | 2002 |
DJ, Shuster JJ, Carroll AJ, Heerema NA, Camitta BM: Near triploidy, near tetraploidy in B-precursor ALL: the POG experience Presented by Dr. Camitta at the International Acute Lymphocytic Leukemia Rare Chromosome meeting,Vienna, Austria, April, 2002 | 2002 |
Savasan S, Stout M, Ozdimer O, Buck S, Pullen J, Ravindranath Y: The role of oxidative metabolism in In Vitro drug response in childhood AML and T-ALL Blood, 2001; 98:311a(Poster presentation, ASH) | 2001 |
Borowitz MJ, Shuster J, Viswanatha DS, Willman CS, Montgomery K, Pullen J, Carroll AJ, Camitta B: Correlation of end-induction minimal residual disease (MRD) in childhood acute lymphoblastic leukemia with clinical and biological risk factors. A Children's Oncology Group study Blood, 2001; 98:841a(Platform presentation, ASH) | 2001 |
Fernandes C, Leclerc GJ, Atlman-Hamandzic S, Shuster J, Pullen J, Camitta B, Safa AR, Barredo JC: Quantitative expression of multidrug resistance related protein (MRPI) and lung resistance protein (LRP) by real-time RT-PCR does not predict treatment outcome and survival in children with T-linage acute lymphoblastic leukemia Blood, 2001; 98:318a(Poster presentation, ASH) | 2001 |
Cox JA, Megason GC, Iyer RV, Loftis SF, Sullivan S, Smith MG, Mitchell T, Pullen DJ: Nasopharyngeal carcinoma in a patient with dominant dystrophic epidermolysis bullosa J Inves Med 49(1):106A, 2001 | 2001 |
Pullen J: Children's Oncology Group Designation for Low Risk Group in Childhood Acute Lymphocytic Leukemia American Society of Hematology Educational Workshop, December 3, 2000, San Francisco, CA | 2000 |
Shuster J, Link M, Camitta B, Pullen J, Behm F: Group sequential design of case-control studies for pediatric acute lyphoblastic leukemia cell bank International Society for Clinical Biostatistics, Trent, Italy, 9/4-8/2000 | 2000 |
Viswanatha DS, Bartolo C, Chen I-M, Camitta B, Pullen J, Willman C, Borowitz M: Comparisons of polymerase chain reaction and flow cytometry for the detection of minimal residual disease in pediatric acute lymphoblastic leukemia: A Pediatric Oncology Group study Blood, 2000 ;96:314a(Poster presentation, ASH) | 2000 |
Smith MG, Pullen DJ, Megason G, Mitchell T, Iyer RV: Streprococcus pneumoniae endophthalmitis in a patient with homozygous sickle cell disease Proceedings of 24th Annual Meeting of the National Sickle Cell Diseae Program, pg 187a, 2000 (poster presentation, Philadelphia PA, April 9-12, 2000) | 2000 |
Megason G, Weitman S, Blaney S, Winick N, Kuhn J, Pullen J, Bernstein M: A trial of 6-hyroxymethylacylfulvene (MGI-114) in children with solid tumors, a Pediatric Oncology Group phase I cooperative agreement study Proc Amer Soc Clin Oncol, 2000; 19:201a | 2000 |
Mitchell TE, Smith MG, Iyer RV, Pullen DJ: Xeroderma pigmentosum presenting as squamous cell carcinoma of the eyelid in a patient with sickle cell disease Proceedings of 24th Annual Meeting of the National Sickle Cell Disease Program, pg 165a, 2000 (poster presentation, Philadelphia PA, April 9-12, 2000) | 2000 |
Broome HE, Yu AL, Diccianni M, Pullen J, Monia BP Inhibition of BCL-xL expression sensitizes T-cell acute lymphocytic leukemia cells to chemotherapeutic drugs. Blood. 1999; 94:226b | 1999 |
Wacker P, Land VJ, Camitta BM, Kurtzberg J, Pullen J, Shuster JJ Allergy to E-coli L-asparaginase has no significant correlation with prognosis of childhood B-pecursor ALL: A Pediatric Oncology Group study. Med Pediatr Oncol. 1999;33:216 (Presented, SIOP/ASPHO) | 1999 |
Mitchell TE, Smith MJ, Iyer RV, Pullen DJ, Jones BP Xeroderma pigmentosum presenting as squamous cell carcinoma of the eyelid in a patient with sickle cell disease. J Invest Med. 1999;47:115a (poster presentation) | 1999 |
Rubnitz JE, Camitta BM, Raimondi SC, Carroll AJ, Borowitz MJ, Shuster JJ, Link MP, Pullen DJ, Downing JR, Behm FG, Mahmoud H, Pui C-H Childhood acute lymphoblastic leukemia with the MLL-ENL fusion and t(11;19)(q23;p13.3): Favorable prognosis in T-cell cases. Blood. 1998;92:312a (presented, ASH) | 1998 |
Weir E, Carroll A, Pullen J, Head D, Camitta B, True mixed-lineage leukemia is a rare disease with poor outcome. A Pediatric Oncology Group study. Blood. 1998;92:398a (poster presentation, ASH) | 1998 |
Kaleem Z, Shuster JJ, Carroll AJ, Borowitz MJ, Pullen DJ, Camitta BM, Zutter MM, Watson MS Acute lymphoblastic leukemia with t(8;14)(q11;q32): A Pediatric Oncology Group study. Blood. 1998;92:398a (poster presentation, ASH) | 1998 |
Shah SJ, Taub JW, Radewan TL, Fu W, Moore D, Pollock BH, Zhang L, Amylon M, Behm FG, Pullen J, Ravindranath Y, Matherly LH Relationship of p15 and p16 gene deletions to elevated dihydrofolate reductase in childhood acute lymphoblastic leukemia. Blood. 1998;92:220a (poster presentation, ASH) | 1998 |
Li P, Shuster JJ, Pullen DJ, Borowitz MJ, Camitta BM, Carroll AJ RT-PCR detection of TEL/AML1 and AML1/TEL chimeric transcripts in children with acute lymphoblastic leukemia: A Pediatric Oncology Group study. ) Blood. 1998;92:392a (poster presentation, ASH | 1998 |
Wacker P, Shuster JJ, Pullen J, Humbert J, Land VJ, Mahoney DH, Lauer SJ, Look AT, Borowitz M, Carroll AJ, Camitta BM Interaction amonst gender, prognostic factors, and time in children with B-precursor acute lymphoblastic leukemia. Presented, International Society of Pediatric Oncology, 1998 | 1998 |
Whitehead VM, Payment C, Vuchich MJ, Cooley L, Lauer SJ, Mahoney DJ, Shuster JJ, Bernstein ML, Kamen BA, Look AT, Pullen DJ, Camitta B CR) The TEL-AML1 translocation and methotrexate polyglutamate levels in childhood B-progenitor cell acute lymphoblastic leukemia: A Pediatric Oncology Group study. Proc Am Assoc Cancer Res. 1998;39:329 (poster presentation, AACR | 1998 |
Batova A, Diccianni MB, Yu J, Bridgeman L, Pullen J, Amylon MJ, Yu AL Use of alanosine as a methylthioadenosine phosphorylase-selective therapy for T-cell acute lymphoblastic leukemia. Proc Am Assoc Cancer Res. 1998;39:470 (poster presentation, AACR) | 1998 |
Omura-Minamisawa M, Diccianni MB, Batova A, Pullen J, Bowman WP, Yu AL Inactivation of p16 cell cycle regulatory pathway by specific targeting of p16 but not the downstream components in T-cell acute lymphoblastic leukemia: A Pediatric Oncology Group study. Blood. 1997;90:492a (presented, ASH) | 1997 |
Hunger SP, Fall MZ, Camitta BM, Carroll AJ, Link MP, Lauer SJ, Mahoney DH, Pullen DJ, Shuster JJ, Steuber CP, Cleary ML E2A-PBX1 chimeric transcript status at end of consolidation is not predictive of treatment outcome in childhood acute lymphoblastic leukemias with a t(1;19)(q23;p13): a Pediatric Oncology Group study. Blood. 1997;90:423a | 1997 |
Borowitz MJ, Rubnitz J, Nash M, Pullen DJ, Camitta B Predictability of the TEL-AML1 rearrangement from surface antigen phenotype in childhood B-precursor ALL. A Pediatric Oncology Group study. Blood. 1997;0:210b | 1997 |
Abish S, Carroll A, Shuster J, Camitta B, Pullen J A comparison of the balanced and unbalanced 1:19 translocation in childhood acute lymphoblastic leukemia: A Pediatric Oncology Group study. Blood. 1997;90:185a (Poster presentation, ASH) | 1997 |
Maloney KW, Rubnitz JE, Cleary ML, Frankel L, Hakami N, Link MP, Pullen DJ, Hunger SP Lack of homozygous p16INK4A (p16) or p15INK4B (p115) gene deletion in infant acute lymphoblastic leukemia. Proc Am Soc Clin Onco. 1997; 16:515a (presented, ASCO) | 1997 |
Harris MB, Land VJ, Shuster JJ, Borowitz MJ, Behm FG, Pullen DJ Treatment of childhood acute lymphoblastic leukemia with consolidation of remission using anti-metabolite based therapy: A Pediatric Oncology Group study. Proc Am Soc Clin Oncol. 1997;16:515a (presented, ASCO) | 1997 |
Shuster JJ, Camitta BM, Pullen J, Borowitz MJ, Carroll AJ, Look AT, Mahoney DH, Lauer SJ, Land VF Identification of newly diagnosed children with acute lymphocytic leukemia at high risk for relapse. Proc Marrow Transplantation in Children, July 1996, Ft. Lauderdale FL (presented) | 1996 |
Yu AL, Batova A, Diccianni MB, Pullen J, Link MP, Yu J Preferential inactivation of p15 INK4B but not p16 INK4A by hypermethylation in T-cell acute lymphocytic leukemia. Blood. 1996;88(10):1408 (Presented, ASH) | 1996 |
Maloney KW, Rubnitz ME, Cleary ML, Frankel L, Hakami N, Link MP, Pullen DJ, Hunger SP Lack of ETV6 (TEL) Rearrangements in infant acute lymphoblastic leukemia. Blood. 1996;88(10):72a (presented, ASH) | 1996 |
Rubnitz JE, Shuster JJ, Land VJ, Link MP, Pullen DJ, Camitta BM, Pui C-H, Downing JR, Behm FG Case-control study of children with acute lymphoblastic leukemia confirms the favorable impact of TEL gene rearangements: A Pediatric Oncology Group study. Blood. 1996;88(10):450a (presented, ASH) | 1996 |
Mahoney DH, Nitschke R, Shuster J, Winick N, Lauer S, Pullen, Steuber P, Camitta B Comparison of intensive methotrexate/mercaptopurine vs low-dose repetitive MTX/MP for lower risk acute lymphoblastic leukemia. A Pediatric Oncology Group randomized phase III study. Proc Am Soc Clin Onocl. 1996;15:336 (presented ASCO) | 1996 |
Harris MB, Land VJ, Shuster JJ, Borowitz MJ, Behm FG, Pullen DJ Consolidation therapy with intermediate dose methotrexate (IDM) alone, or IDM and L-asparaginase, or IDM and cytosine arabinoside in standard risk acute lymphoblastic leukemia of childhood: A Pediatric Oncology Group study. Blood. 1996;88(10):668a (presented, ASH) | 1996 |
Behm FG, Carroll A, Shuster J, Camitta B, Link M, Lauer S, Land V, Steuber P, Crist W, Pullen DJ Rearrangement of the MLL gene identifies a subgroup of non-infant children with precursor-B ALL at high risk for treatment failures. A Pediatric Oncology Group study. Proc Am Assoc Cancer Res. 1996;37:186 (presented AACR) | 1996 |
Whitehead VM, Vuchich M-J, Carroll A, Lauer S, Mahoney D, Shuster J, Payment C, Bernstein M, Akabutu J, Bowen T, Kamen B, Ravindranath Y, Ememi A, Beardsley P, Pullen J, Camitta B Translocations involving chromosomes 12p, methotrexate metabolism and outcome in childhood B-progenitor cell acute lymphoblastic leukemia: A Pediatric Oncology Group pharmacology pilot study. Proc Am Assoc Cancer Res. 1996; 37:381 (presented AACR) | 1996 |
Alvarado CS, Austin GE, Borowitz M, Shuster J, Zaki S, Hakami N, Pullen J Myeloperoxidase (PO) gene expression in infant leukemia: A Pediatric Oncology Group study. Blood. 1995;86(10):330a (presented ASH) | 1995 |
Yu AL, Diccianni MB, Batova A, Vu T, Pullen J, Amylon M, Pollock B, Yu J High frequency alterations of the p16 and p15, but not p18, DCK inhibitors in T cell acute lymphoblastic leukemia. Blood. 1995;86(10):268a (presented ASH) | 1995 |
Borowitz MJ, Shuster J, Carroll AJ, Look AT, Camitta B, Mahoney D, Lauer S, Pullen DJ Prognostic significance of antigen fluorescence intensity (FI) in B-precursor acute lymphoblatic leukemia: Early outcome data from the Pediatric Oncology Group. Blood. 1995;86(10):41a (presented ASH) | 1995 |
Lauer SJ, Toledano S, Winick N, Munoz L, Mahoney D, Pullen J, Steuber CP, Shuster J, Camitta B A comparison of early intensive methotrexate/mercaptopurine vs early intensive alternating chemotherapy for high risk acute lymphoblastic leukemia. A Pediatric Oncology Group randomized phase III study. Proc Amer Soc Clinic Oncol. 1995;14:342 (presented, ASCO) | 1995 |
Camitta B, Land V, Lauer S, Mahoney D, Pullen J, Shuster J Risk adapted therapy for ALL: The Pediatric Oncology Group experience. Presented Acute Leukemias VI: Prognostic Factors and Treatment Strategies. Munster, Germany, 2/28/95 | 1995 |
Whitehead VM, Vuchich M-J, Carroll AJ, Lauer SJ, Mahoney D, Shuster JJ, Payment C, Koch PA, Akabutu JJ, Bowen T, Kamen BA, Ravindranath Y, Emami A, Beardsley GP, Pullen DJ, Camitta B Relation of methotrexate polyglutamate (MTXPG) accumulation in lymphoblasts to trisomy of both chromosomes 4 and 10 and to ploidy in childhood acute lymphoblastic leukemia: A Pediatric Oncology Group study. Blood. 1994;84(10):515a (presented, ASH) | 1994 |
Head DR, Borowitz M, Cerezo L, Craven C, Boyett J, Falletta J, Crist W, Pullen J, Humphrey B Reliability of punctate acid phosphatase positivity as a marker of T-cell acute lymphocytic leukemia in childhood. Blood 64(5):191a, 1984 | 1994 |
Mahmoud HH, Schwartz C, Shuster J, Pui CH, Behm F, Amylon M, Raimondi S, Borowitz M, Link M, Pullen J, Camitta B, Hakami N, Crist W, Carroll A The (11;19) translocation is associated with poor outcome in infants with acute lymphoblastic leukemia. A collaborative study of the POG and SJCRH. Med Ped Oncol. 1994, XXVIth Annual Meeting, International Society of Pediatric Oncology (SIOP), Paris, September 1994 | 1994 |
Megason G, Moulder S, Pullen D The use of in vitro culture assays to predict in vivo response to various therapeutic modalities in a patient with Diamond-¬Blackfan anemia. ) J Cell Biochem. 1994;18A:33 (Poster presentation, 1994 Keystone Symposia on Hematopoiesis | 1994 |
Lauer S, Shuster J, Kirchner P, Kiefer G, Pullen J, Camitta B, Land V Prognostic significance of cerebrospinal fluid lymphoblasts at diagnosis in children with acute lymphoblastic leukemia. ) Proc Amer Soc Clin Onco. 1994; 13:317 (Presented, ASCO | 1994 |
Pettenati MJ, Rao PN, Schnell S, Carroll AJ, Harris MJ, Pullen J, Martin PL Retrospective/ prospective investigation using FISH to detect chromosome 4 and 10 aneuploidy as a predictor of very good risk pediatric ALL. Am J Hum Genet. 1993;53:a342 (Poster presentation, American Society of Human Genetics) | 1993 |
Moulder S, Megason G, Pullen D The use of cell culture models to determine a possible course of treatment for a patient with Diamond-Blackfan anemia. Clin Res. 1993;40(4):730a (Poster presentation, Southern Society for Pediatric Research) | 1993 |
Megason GC, Hardy CL, DeBauche DM, Lewis RE, Pullen DJ Synergistic effects of hematopoietic cytokines on in vitro cultures from patients with acute myelogenous leukemia. Blood. 1992;82(10):651a | 1993 |
Herden MJ, DeBauche DM, Pullen DJ . Detection of the Mbcr-abl rearrangement by interphase-fluorescent in-situ hybridization in CML Blood. 1993;82(10):525a | 1993 |
Rubnitz JE, Link JP, Shuster JJ, Carroll AJ, Hakami N, Frankel L, Pullen DJ, Cleary ML Frequency and significance of HRX rearrangements in infant leukemia. Blood. 1993;82(10):190a (poster presentation, ASH) | 1993 |
Megason GC, Vedanarayanan V, Iyer RV, Belue A, Pullen J Coagulation abnormalities in patients with sickle cell disease and cerebrovascular accidents. Poster presentation, Eighteenth Annual Meeting of National Sickle Cell Disease Program, May, 1993 | 1993 |
Pui C-H, Raimondi SC, Borowitz MJ, Land VJ, Behm FG, Pullen DJ, Hancock ML, Shuster JJ, Steuber CP, Crist WM, Civin CI, Carroll AJ Acute lymphoblastic leukemia in children with Down syndrome. Proc Amer Soc Clin Onco. 1993; 12:319 | 1993 |
Borowitz MJ, Carroll AJ, Hunger SP, Shuster JJ, Crist WM, Cleary ML, Pullen DJ The t(1;19) (E2A-PBX1) translocation in childhood ALL is associated with a specific immunophenotype. Modern Pathol. 1993;6:86a | 1993 |
Megason GC, Hatten BH, Kruckeberg WC, Pullen DJ The evaluation of secondary hyperphenylalaninemia by measuring the level of phenylalanine in the cerebrospinal fluid of children receiving methotrexate chemotherapy. Proceedings of the Greenwood Genetic Center. 1992;12:153 (Poster presentation, Southern Genetics Group, 7/10/92 | 1993 |
Megason GC, Smith J, Iyer RV, Pullen DJ, Carey T Aplastic crisis due to human parvovirus (B19) in two patients with glucose 6 phosphate dehydrogenase deficiency. Clinical Research. 1992;40(4):785a (Poster presentation, SSPR) | 1992 |
Iyer RV, Megason GC, Herden MJ, Smith MG, Pullen DJ Tri-lineage response to granulocyte macrophage colony stimulating factor in the treatment of severe refractory aplastic anemia. Blood. 1992;80(10)415a | 1992 |
Smith JC, Megason GC, Iyer RV, Pullen DJ Epidemiology of human parvovirus (B19) infections and aplastic crisis in patients with hereditary hemolytic anemias treated in tertiary care centers. Proc Southern Medical Assoc. 1992; abst P73 (presented, SMA) | 1992 |
Bowman WP, Shuster J, Cook B, Behm F, Pullen J, Berard C, Murphy S Improved survival for children with B cell (SIg+) acute lymphoblastic leukemia (B-ALL) and stage IV small non- cleaved cell lymphoma. Proc Amer Soc Clin Oncol. 1992;11:277 (presented, ASCO) | 1992 |
Quddus FF, Leventhal BG, Boyett JM, Pullen DJ, Borowitz MJ, Shuster JJ, Kato GJ Higher glucocorticoid receptor level is a favorable prognostic factor in childhood acute lymphocytic leukemia: A Pediatric Oncology Group study. Blood. 1991;78(10):391 (poster presentation, ASH) | 1991 |
Abshire TC, Buchanan GR, Jackson JF, Shuster JJ, Brock B, Head D, Behm FG, Crist WM, Link MP, Borowitz M, Pullen DJ Morphologic, immunophenotypic, and cytogenetic studies at time of first marrow relapse in children with acute lymphoblastic leukemia: Comparison with results at diagnosis and effect on outcome. Blood. 1991;78(10):171a (presented, ASH) | 1991 |
Bash RO, Crist WM, Link MP, Shuster JJ, Amylon M, Pullen J, Buchanan GR, Baer R: \ Clinical features and outcome in childhood T-cell acute lymphoblastic leukemia (T-ALL) with the tal rearrangement. Blood. 1991;78(10):325 (poster presentation, ASH) | 1991 |
Shuster J, Carroll A, Look T, Borowitz M, Crist W, Pullen J, Steuber P, Land V Trisomy of chromosome 4,10, or 18 and hyperdiploidy predict better outcome in B-progenitor pediatric acute lymphoblastic leukemia: A Pediatric Oncology Group study. Proc Amer Soc Clin Oncol 10:234, 1991 (Presented, ASCO) | 1991 |
Shuster J, Look T, Crist W, Borowitz M, Carroll A, Pullen J, Steuber P, Land V Clinical features and tumor cell DNA index improve prediction of treatment outcome in pediatric B-progenitor acute lymphoblastic leukemia: A Pediatric Oncology Group study. Proc Amer Soc Clin Oncol. 1991;10:234 (Presented, ASCO) | 1991 |
Borowitz MJ, Carroll AJ, Shuster JJ, Behm FG, Pullen DJ, Frankel L, Crist WM, Land V A unique immunophenotype defines cases of childhood acute lymphoblastic leukemia with chromosome 11q23 abnormalities and poor outcome. A Pediatric Oncology Group study. ) Modern Pathol. 1991;4:68a (Presented, US and Canadian Academy of Pathology | 1991 |
Borowitz MJ, Shuster JJ, Steuber P, Pullen DJ, Crist WM Intraclonal heterogeneity of cell surface antigen expression in chiodhood B-precursor acute lymphoblastic leukemia: A Pediatric Oncology Group study. Cytometry Supplement. 1991;5:43-44 (presented, XV Congress of the International Society for Analytical Cytology) | 1991 |
Whitehead VM, Vuchich M-J, Carroll AJ, Shuster JJ, Lauer S, Mahoney D, Akabutu J, Bowen T, Beardsley P, Leclerc J-M, Pullen DJ Methotrexate metabolism in lymphoblasts with hyperdiploidy and/or translocations in children with acute lymphoblastic leukemia: A Pediatric Oncology Group study. Blood. 1990;76(10):335a | 1990 |
Pui C-H, Frankel LS, Carroll AJ, Raimondi SC, Shuster JJ, Head DR, Crist WM, Land VJ, Pullen DJ, Steuber CP, Behm FG, Borowitz MJ Childhood acute lymphoblastic leukemia with the t(4;11)(q21;q23). Blood. 1990;76(10):310a (presented, ASH) | 1990 |
Abdel-Mageed A, Ragab AH, Shuster JJ, Pullen J, van Eys J, Sullivan MP, Boyett J, Borowitz M, Frankel LS, Crist WM Children with Down's syndrome and acute lymphocytic leukemia: Presenting features and outcome of therapy: A Pediatric Oncolgy Group study. Proc Amer Soc Clin Oncol. 1990;9:216 (presented, ASCO) | 1990 |
Land VJ, Shuster JJ, Carroll AJ, Borowitz MJ, Harris MB, Pullen DJ, Look AT A DNA index greater than 1.16 in B-precursor childhood acute lymphoblastic leukemia predicts a 95 percent 3-year event-free survival. Blood. 1990;76(10):292a (presented, ASH) | 1990 |
Pui C-H, Carroll AJ, Head D, Raimondi SC, Land VJ, Crist WM, Link MP, Behm FG, Nash M, Pullen DJ, Look AT Near-triploidy and near-tetraploidy in acute lymphoblastic leukemia of childhood. Proc Amer Soc Clin Oncol. 1990;9:216 (presented, ASCO) | 1990 |
Carroll AJ, Crist WM, Shuster J, Behm FG, Vietti TJ, Ragab A, Pullen DJ, Land VJ The poor prognosis of children with pre-B acute lymphoblastic leukemia is strongly associated with the t(1;19)(q23;p13). Blood. 1989;74(7):197a (presented, ASH) | 1989 |
Land VJ, Shuster JJ, Pullen J, Harris M, Krance RA, Castleberry R, Akabutu J, Barbosa JL, Rosen D Unexpectedly high incidence of allergic reactions with weekly high dose asparaginase early intensification therapy in children with newly diagnosed non-T, non-B acute lymphocytic leukemia. A Pediatric Oncology Group study. Proc Amer Soc Clin Oncol. 1989;8:215 | 1989 |
Pui C-H, Carroll AJ, Raimondi SC, Land VJ, Crist WM, Williams DL, Pullen DJ, Borowitz MJ, Behm FG, Look AT Near-haploidy and hypodiploidy <45 in acute lymphoblastic leukemia of childhood. Blood. 1989;74(7):158a (presented, ASH) | 1989 |
Borowitz M, Shuster J, Behm F, Look T, Carroll A, Land V, Pullen J, Crist W Prognostic significance of surface antigen phenotype in B-precursor ALL: A recursive partitioning analysis. Proc Amer Assn Ca Re. 1989; 30:230 (Presented, AACR) | 1989 |
Land VJ, Pullen DJ, Shuster JJ, Alvarado C, Amylon M, Harris MB Continuing improvement of outcome in childhood non-T, non-B acute lymphocytic leukemia: Pediatric Oncology Group experience in the 1980's. Blood. 1989;74(7):80a (poster presentation, ASH) | 1989 |
Russo C, Carroll A, Borowitz M, Kohler S, Shannon K, Forman E, Cook B, Amylon M, Pullen J, Link M The Philadelphia chromosome with monosomy 7 in childhood acute lymphoblastic leukemia. Proc Amer Soc Clin Oncol. 1989;8:212(Presented, ASCO) | 1989 |
Pullen J, Boyett J, Crist W, Johnson W, Iyer R, Frankel L, Gross S, Dubowy R, Berry D, Vietti T Intermediate dose methotrexate pulses during maintennce provide significantly improved protection for the testicular sanctuary in boys with non-T, non-B acute lymphocytic leukemia (ALL). A Pediatric Oncology Group study. Proc Amer Soc Clin Oncol. 1989;8:211 (Presented, ASCO) | 1989 |
Borowitz MJ, Shuster JJ, Civin CI, Behm FG, Carroll A, Crist W, Pullen DJ CD34 expression is a favorable prognostic marker in B-precursor childhood acute lymphoblastic leukemia. Modern Pathol. 1989;2:11A (Presented, United States and Canadian Academy of Pathology) | 1989 |
Carroll AJ, Raimondi SC, Borowitz MJ, Amylon MD, Rivera G, Pullen DJ, Crist WM A new nonrandom 8;14 translocation in children with acute lymphoblastic leukemia. Am J Hum Genet. 1988;43:A21 | 1988 |
Crist W, Boyett J, Frankel L, Iyer R, van Eys J, Sullivan M, Harris M, Ravindranath Y, Pullen J Extended triple intrathecal chemotherapy (TIC) is highly effective and superior to brief TIC and intermediate-dose MTX (IDM) as CNS prophylaxis in non-T, non-B ALL. A Pediatric Oncology Group study. Presented August 1988, International Society of Paediatric Oncology SIOP XX meeting | 1988 |
Frankel LS, Shuster J, Dubowy R, Bowman P, Chauvenet A, Carroll AJ, Pullen J Seeking a better understanding of why infants with leukemia fail to maintain r¬mission. A Pediatric Oncology Group study. Proc Amer Soc Clin Oncol. 1988;7:193 | 1988 |
Link MP, Borowitz MJ, Behm FG, Jackson A, Brock B, Shuster JJ, Pullen J Rapid immunodiagnosis of childhood acute lymphoblastic leukemia using a screening kit. Proc Amer Soc Clin Onco. 1988; 7:180 | 1988 |
Amylon M, Murphy S, Pullen J Treatment of lymphoid malignancies according to immune phenotype: Preliminary results in T-cell disease. Proc Amer Soc Clin Oncol. 1988;7:225 (Presented, ASCO) | 1988 |
Jackson JF, Boyett J, Pullen J, Brock B, Patterson R, Land V, Borowitz M, Crist W Improved prognosis in childhood acute lymphocytic leukemia (ALL) with hyper¬diploidy correlates with extra chromosome six. A Pediatric Oncology Group study. Proc Amer Soc Clin Onco. 1988; 7:178 (Presented, ASCO) | 1988 |
Borowitz MJ, Civin CI, Behm FG, Falletta JM, Shuster J, Carroll A, Look T, Pullen DJ, Crist WM Phenotypes encountered in B-lineage acute lymphoblastic leukemia (ALL) do not reflect stages of normal B-cell differentiation. A Pedia¬tric Oncology Group study. Lab Invest. 1988;58(1):11A (Presented, International Academy of Pathology) | 1988 |
Nuss R, Kirchingman G, Cross A, Zipf T, Antoun G, Bernstein I, Behm F, Pullen D, Crist W, Mirro J, Gorrha R T cell receptor gene rearrangements distinguish between infants and children with CALLA negative acute lymphoblastic leukemia. Blood. 1987;70(5):265a (presented, ASH) | 1987 |
Sullivan MP, Crist W, Pullen J, Jackson J, Head D, Borowitz M, Murphy S, Shuster J Childhood B-cell acute lymphocytic leukemia (ALL) is unexpectedly clinically heterogeneous: A Pediatric Oncology Group study. Proc Amer Soc Clin Onco. 1987; 6:148 (Presented, ASCO) | 1987 |
Carroll AJ, Link MP, Pullen DJ, Shuster JJ, Crist WM Cytogenetic features in children with T-cell acute lymphoblastic leukemia. Blood. 1987;70(5):276a (Presented, ASH) | 1987 |
Frankel LS, Ochs J, Shuster J, Dubowy R, Bowman P, Hockenberry M, Leventhal B, Carroll AJ, Pullen J Pilot protocol improves remission for infant leukemia and provides detailed laboratory characterization. Proc Amer Soc Clin Oncol. 1987;6:161 | 1987 |
Pullen J, Boyett J, Borowitz M, Dowell B, Falletta J, Krejmas N, Sexauer C, Crist W How important is common acute lymphocytic leukemia antigen (CALL) negativity as a prognostic factor in children excluding infants with B-precursor acute lymphocytic leukemia (ALL)? A Pediatric Oncology Group study. Proc Amer Soc Clin Oncol. 1987;6:151(Presented, ASCO) | 1987 |
Hurwitz C, Loken M, Graham M, Karp J, Borowitz M, Pullen J, Civin C Asynchro¬nous antigen epression in B-lineage acute lymphoblastic leukemia (ALL). Blood. 1987;70(5):260a | 1987 |
Boyett J, Pullen J, Jackson J, Vietti T, Borowitz M, Patterson R, Winick N, Crist W Pre-B phenotype of childhood acute lymphocytic leukemia (ALL) has prognostic importance independent of cytogenetic and other known risk factors. A Pediatric Oncology Group study. Blood. 1987; 70(5):198a (Presented, ASH). | 1987 |
Carroll AJ, Link MP, Ragab AH, Pullen DJ, Crist WM A nonrandom tramslocation, t(1;14), in children with T-cell acute lymphoblastic leukemia. Am J Hum Genet. 1987;41:A24 (Presented American Society of Human Genetics) | 1987 |
Carroll AJ, Raimondi SC, Pullen DJ, Crist WM tdic (9;12): A non-random chromosome abnormality in childhood B-cell acute lymphoblastic leukemia (ALL). Am J Hum Genet. 1986;39:A28 (presented, American Society of Human Genetics) | 1986 |
Carroll AJ, Frankel LS, Pullen DJ, Crist WM Acquired cytogenetic abnormalities in blast cells of infants with acute lymphoblastic leukemia. Blood. 1986;68(5):252a (Presented, ASH) | 1986 |
Downing J, Crist W, Pullen J, Vietti T, Grossi C, Prasthofer E, Burrows P T¬-cell antigen receptor B chain (Ti) and immunoglobulin (IG) gene rearrangements (REAR) in childhood T-cell acute lymphoblastic leukemia (T-ALL): Evidence for lineage infidelity. Lab Inves. 1986; 54(i):17a | 1986 |
Scroggs M, Boyett J, Falletta J, Pullen DJ, Jackson J, Russell E, Crist W, Borowitz M Clinicopathologic significance of immunophenotypic subgroups of B-¬lineage acute lymphocytic leukemia (ALL). A Pediatric Oncology Group (POG) study. Proc Amer Assoc Cancer. 1986 Res 27:201 (Presented, AACR) | 1986 |
Frankel LS, Pullen J, Boyett J, Eastment C, Ragab A, Hvizdala E, Berry D, Sexauer C, Crist W, Vietti T Excessive drug toxicity in children with Down's syndrome (DS) treated for acute lymphocytic leukemia (ALL) despite similarity of clinical and biological features to other patients. Proc Amer Soc Clin Oncol. 1986;5:161 | 1986 |
Craven CM, Head DR, Pullen J, Ligorsky R Specific esterase (SE) staining in monoblastic (M5) leukemia. Blood 66(5):172a, 1985 | 1985 |
Russell E, Mohanakumar T, Boyett J, Pullen J, Crist W, Borowitz J, Falletta J, Leventhal B, Harris M, Maurer HM for the Pediatric Oncology Group Receptors for peanut agglutinin in childhood acute lymphoblastic leukemia: Clinical and biologic correlates. Blood 66(5):228a, 1985 | 1985 |
Pullen J, Jackson J, Crist W, Carroll A, Boyett J, Borowitz M, Brock B, Iyer R, Buchanan G, Head D, McWilliams N, Ragab A Philadelphia chromosome positive (Ph+) acute lymphocytic leukemia (ALL) in children has clinical and biologic features that predict poor prognosis and is cytogenetically and immunopheno¬typically heterogeneous. Blood 66(5):181a, 1985 (Presented, ASH) | 1985 |
Falletta JM, Pullen DJ, Shuster JJ, Borowitz MJ for the Pediatric Oncology Group E-rosette positive (ER+), T antigen positive (T cell) acute lymphocytic leukemia (ALL) - Patterns of relapse. Pediatr Res 19(4):261A, 1985 | 1985 |
Adams JG, Morrison WT, Pullen DJ, Abney RL, Steinberg MJ Hemoglobin Mississippi (MS): A new hemoglobin variant with three distinct electrophoretic mobilities. Clin Res 33(2):603A, 1985 | 1985 |
Weiner M, Borowitz M, Boyett J, Civin K, Metzgar R, McKolnis J, Crist W, Dowell B, Pullen J for the Pediatric Oncology Group ) Clinical pathologic aspects of myeloid antigen positivity in pediatric patients with acute lymphoblastic leukemia (ALL). Proc Amer Soc Clin Oncol 4:172, 1985 (Presented, ASCO | 1985 |
Pullen J, Crist W, Boyett J, Falletta J, van Eys J, Borowitz M, Jackson J, Dowell B, Frankel L, Quddus F, Ragab A, Vietti T Infants have biologically different and clinically more aggressive acute lymphocytic leukemia (ALL) than older children. Proc Amer Clin Oncol 4:163, 1985 (Presented, ASCO) | 1985 |
Boyett JM, Pullen DJ, Sullivan MP, Falletta JM, Humphrey GB, Starling KA, Land VJ, Vats TS, Ragab AH, Crist WM for the Pediatric Oncology Group Modified LSA2¬L2 treatment in 53 children with E-rosette-positive T-cell leukemia (T-ALL): Cures and factors predictive of CNS relapse. Proc Amer Soc Clin Oncol 4:163, 1985 | 1985 |
van Eys J, Berry D, Crist W, Doering E, Fernbach D, Pullen J, Shuster J for the Pediatric Oncology Group Effect of Trimethoprim/Sulfamethoxazole (TS) prophylaxis on outcome of childhood acute lymphocytic leukemia (ALL). Proc Amer Soc Clin Oncol 4:154, 1985 (Presented, ASCO) | 1985 |
van Eys J, Pullen J, Head D, Boyett J, Crist W, Falletta J, Humphrey GB, Jackson J, Riccardi V, Brock B The French American British (FAB) classification: The Pediatric Oncology Group (POG) experience with acute lymphocytic leukemia (ALL). Blood 62(5):185a, 1983 (Poster presentation, ASH) | 1984 |
Grossi C, Crist W, Prasthofer E, Civin C, Griffith R, Harris D, Humphrey B, Freeman A, Pullen J Maturational staging of childhood T-cell malignancies: Cytochemical and ultrastructural studies complement immunologic analysis. Blood 64(5):147a, 1984 (Presented, ASH) | 1984 |
Crist W, Pullen J, Boyett J, Falletta J, van Eys J, Borowitz M, Jackson J, Dowell B, Quddus F, Ragab A, Vietti T Clinical and biologic features predict poor prognosis in acute lymphocytic leukmia (ALL) in infants. Presented at the International Society of Pediatric Oncology Meeting, Barcelona, Spain. SIOP Abstracts page 198, September 1984 | 1984 |
Quddus FF, Kaufmann SH, Boyett J, Pullen J, Borowitz M, Crist W, Leventhal BG: Correlation of lymphoblast glucocorticoid receptor (GR) number and patient characteristics in childhood acute lymphocytic leukemia (ALL). Proc Amer Assoc Cancer Res 25:206, 1984 (Poster presentation, AACR) | 1984 |
Borowitz MJ, Boyett JM, Dowell BL, Pullen DJ, Metzgar RS, Humphrey GB, van Eys J, Falletta JM Clinicopathologic aspects of E rosette negative T cell acute lymphoblastic leukemia (T-ALL). Proc Amer Soc Clin Oncol 3:18, 1984 | 1984 |
Dowell BL, Boyett JM, Borowitz MJ, Falletta JM, Pullen DJ, Crist WM, van Eys J, Metzgar RS, Starling KA, Humphrey GB Immunologic and clinicopathologic features of common acute lymphocytic leukemia antigen (CALLA)-positive, T cell leukemia. Proc Amer Soc Clin Res 25:783, 1984 (Presented, ASCO) | 1984 |
Pullen J, Crist W, Boyett J, Falletta J, van Eys J, Borowitz M, Jackson J, Dowell B, Russell C, Quddus F, Ragab A, Vietti T Clinical and biologic features predict poor prognosis in adolescent acute lymphocytic leukemia (ALL). Proc Amer Soc Clin Oncol 3:199, 1984 (Presented, ASCO) | 1984 |
van Eys J, Shuster J, Pullen J, Berry D, Crist W, Doering E, Fernbach D, Moore T Intensity of therapy and infections in pediatric leukemia. Proc Amer Soc Clin Oncol 2:80, 1984 (Presented ASCO) | 1984 |
Barger B, Dearth J, Crist W, Humphrey B, Ragab A, Pullen J, Go R, Vietti T, Acton R HLA associations in black and white children with non-T, non-B acute lymphocytic leukemia. Blood 62(5):165a, 1983 | 1984 |
Sullivan MP, Pullen J, Chen T, Moore T, Doering EJ, Falletta JM, Trueworthy R SWOG trial of LSA2-L2 therapy. International Society of Pediatric Oncologists. Budapest, Hungary, 9/23/83 (Presented, SIOP) | 1983 |
Falletta J, Boyett J, Pullen J, Crist W, Humphrey GB, Metzgar R Black children have common acute lymphocytic leukemia (ALL) less often than do white children. Proc Amer Assoc Cancer Res 2:127, 1983 | 1983 |
Humphrey GB, Pincus JK, Pullen DJ, Falletta JM, Metzgar RS, van Eys J, Boyett JM, Shuster JJ AACR) An analysis of two definitions of T-cell leukemia (TCL) by the Pediatric Oncology Group (POG). Proc Amer Assoc Cancer Res 2:127, 1983 (Presented, AACR) | 1983 |
Boyett J, Pullen J, Crist W, van Eys J, Berry D, Leventhal B, Kim T, Ravindranath Y, Dowell B, Roper M Immune phenotype is an independent prognostic factor within non-T, non-B acute lymphocytic leukemia (ALL): Initial WBC is not prognostic within pre-B ALL. Blood 60(5):121a, 1982 (Presented, ASH) | 1982 |
Crist W, Roper M, Jackson J, Pullen J, Humphrey B, Boyett J, Metzgar R, van Eys J, Falletta J, Cooper M Childhood pre-B cell leukemia responds less well to therapy. Presented International Society of Pediatric Oncology XIVth Meeting, Bern, Switzerland. SIOP Abstracts page 13. 9/21-25/82 | 1982 |
Roper M, Crist W, Metzgar R, Ragab A, Smith S, Starling K, Pullen J, Leventhal B, Bartolucci A, Cooper M Monoclonal antibody characterization of surface antigens in childhood T-cell malignancies. Presented International Society of Pediatric Oncology XIVth Meeting, Bern Switzerland. SIOP Abstracts page 59. 9/21-25/82 | 1982 |
Quddus FF, Kaufmann SH, Roper M, Dowell B, Pullen J, Leventhal BG Glucocorticoid receptor (GR) level in pediatric leukemia cells. Proc Amer Clin Oncol 1:131, 1982 | 1982 |
Falletta JM, Pincus JK, Metzgar RS, Pullen DJ, Humphrey GB, Crist WM, Boyett J, van Eys J: Reduced efficacy of vincristine-prednisone in some patients with T¬cell leukemia. Clin Res 29:893A, 1981 (Presented, SSPR) | 1981 |
Roper M, Crist W, Ragab A, Pullen J, Humphrey B, Boyett J, Metzgar R, van Eys J, Nix W, Cooper M: Pre-B cell leukemia differs in its response to therapy. Blood 59(5):150a, 1981 (Presented, ASH) | 1981 |
Humphrey GB, Blackstock R, Falletta JM, Metzgar R, van Eys J, Richie ER, Crist WM, Cooper MD, Pullen DJ, Shuster J, Boyett J, Maurer H, Whitehead VM: Expression of Fc and/or C' receptors on "ontologically immature and mature phenotypes" in acute lymphoblastic leukemia (ALL). Exper Hematol 9(9):79, 1981 (Presented, ISEH) | 1981 |
Sullivan MP, Pullen J, Moore T, Doering EJ, Falletta JM, Trueworthy R, Chen T: Pediatric Oncology Group trial of LSA2-L2 therapy in non-Hodgkin's lymphoma (NHL). Proc Amer Soc Clin Oncol 22:378, 1981 (Presented, ASCO) | 1981 |
Pincus JK, Falletta JM, Metzgar R, Pullen J, Crist W, Humphrey GB, Boyett J: The accuracy of identifying T cell leukemia using E rosetting of bone marrow lymphoblasts. Pediatr Res 15(4):602, 1981 | 1981 |
Pincus JK, Falletta JM, Metzgar R, Pullen J, Crist W, Humphrey GB, Boyett J, van Eys J: Thymocyte antigen in T cell leukemia. Pediatr Res 15(4):584, 1981 | 1981 |
Roper M, Crist W, Metzgar R, Nix W, Smith S, Pullen J, Ragab A, Cooper MD Immune phenotypes in childhood T-cell lymphoid malignancies. Proc Amer Soc Clin Oncol 22:374, 1981 (Presented, ASCO) | 1981 |
van Eys J, Chen TT, Berry D, Moore T, Crist W, Doering E, Fernbach D, Pullen J The effect of drug dosage on outcome and infectious complications in the treatment of childhood lymphocytic leukemia. Proc Amer Soc Clin Oncol 22:478, 1981 | 1981 |
Pincus JK, Falletta JM, Metzgar R, Pullen J, Crist W, Humphrey GB, McKnight MA, van Eys J The accuracy of identifying T cell leukemia using E-rosetting of bone marrow lymphoblasts. Clin Res 28(5):869a, 1980 (Presented, SSPR) | 1980 |
Frankel LS, Wang YM, Pullen J, Nitschke R, Doering EJ High dose intravenous (IV) methotrexate (MTX) with intrathecal (IT) MTX boost in the maintenance of acute lymphocytic leukemia (ALL) in children. Proc Amer Soc Clin Oncol 21:389, 1980 | 1980 |
Pullen J, Crist W, Falletta J, Humphrey G, Metzgar R, van Eys J, Vogler L Immunologic profiles in childhood acute lymphocytic leukemia (ALL). Proc Amer Assoc Cancer Res 21:247, 1980 (Poster presentation, AACR) | 1980 |
Humphrey GB, Crist W, Falletta J, Richie E, Ragab A, Pullen J The implication of thermostable and thermolabile T-cell leukemia in randomized trials (potential for prognostic significance). Proc Amer Assoc Cancer Res 20:289, 1979 | 1979 |
McKnight MA, Falletta JM, Metzgar R, Pullen J, Crist W, Humphrey GB, van Eys J Clinical and laboratory characteristics of T-antigen positive acute lymphocytic leukemia in children. Clin Res 27:816a, 1979 (Presented, SSPR) | 1979 |
Crist W, Vogler L, Sarrif A, Pullen J, Bartolucci A, Falletta J, Humphrey B,van Eys J, Cooper M Clinical and laboratory characterization of pre-B cell leukemia in children. Blood 54(5):183a, 1979 | 1979 |
Humphrey GB, Richie E, Falletta JM, Crist WM, Ragab AH, Pullen J The spectrumof the E receptor on bone marrow blasts in acute lymphoblastic leukemia (ALL) of childhood. Blood 54(5):189a, 1979 | 1979 |
Humphrey GB, Herson J, Pullen J, Crist W, Ragab A, Falletta J The role of thermal stability in the identification of two subsets of T-cell acute lymphoblastic leukemia. Inter Soc Experi Hematol 3:85, 1978 (Presented, ISEH) | 1978 |
Starling KA, Pullen J, Humphrey GB, Crist WM, Vats T, Sabio H Adriamycin, vincristine and prednisone for remission induction in acute myelogenous leukemia. Pediatric Res 11:481, 1977 | 1977 |
Lusher JM, Barnhart MI, Pullen J, Warrier AI Platelet function, ultrastructure, and management in Glanzmann's thrombasthenia. Thrombosis and Haemostasis 38:263, 1977 | 1977 |
Starling KA, Humphrey GB, Pullen J, Vats TS, Dyment P Vincristine and prednisone vs vincristine, prednisone and L-asparaginase for second remission induction in acute leukemia in children. Blood 46:289, 1975 | 1975 |
Lane DM, George SL, Komp D, Lonsdale D, Pullen J, Ragab A, Starling KA Continuous maintenance therapy following either continuous or discontinuous maintenance therapy in childhood leukemia. Proc Amer Soc Clin Oncol 15:166, 1974 | 1974 |
Berry D, Pullen J, Vietti T, Sullivan M, Fernbach D Comparison of prednisolone,vincristine, methotrexate and 6-mercaptopurine (POMP) vs vincristine and prednisone (V-P) induction in childhood acute leukemia. Proc Amer Assoc Cancer Res 15:33, 1974 | 1974 |
Pullen DJ: Platelet function in salicylate intoxication. Proc Southern Soc Pediatr Res, November 1968 (Presented, SSPR) | 1969 |
Pullen J, Boyett J, Frankel L, Iyer R, van Eys J, Crist W, Harris M, Ravindranath Y, Sullivan MP Extended triple intrathecal (T.I.T.) chemotherapy provides effective central nervous system (CNS) prophylaxis for both good and poor prognosis patients with non-T, non-B acute lymphocytic leukemia (ALL): Substitution of in¬termediate dose methotrexate (IDM) for T.I.T. after consolidation provides less effective protection for the CNS. Proc Amer Soc Clin Oncol. 1988;7:176(Presented, ASCO) | 1888 |
Land VJ, Shuster JJ, Pullen J, Harris M, Krance RA, Castleberry R, Akabutu J, Barbosa JL, Rosen D Unexpectedly high incidence of allergic reactions with weekly high dose asparaginase early intensification therapy in children with newly diagnosed non-T, non-B acute lymphocytic leukemia. A Pediatric Oncology Group study. Proc Amer Soc Clin Oncol. 1989;8:215 | |
Thesis | |
Pullen DJ Studies in platelet function. Thesis accepted June, 1969 by the Committee on Graduate Studies in Clinical Depts of the Univ of Tenn in partial fulfillment of requirements for the Degree of Master of Science in Pediatrics | 1969 |
Book Chapter | |
Pullen J: Acute leukemia in children In Rakel, Bope, editors, Conn's Current Therapy. WB Saunders Company, pp 449-454, 2001 | 2001 |
Borowitz MJ, Carroll AJ, Shuster JJ, Look AT, Behm FG, Pullen DJ, Land VJ, Crist WM Use of clinical and laboratory features to define prognostic subgroups in B¬precursor ALL. Experience of the Pediatric Oncology Group. Presented at the International Workshop on Recent Advances in Tumor Cell Biology in Acute Leukemias. Berlin, June 28-29, 1991. Recent Results in Cancer Research. 1993;131:257-269. Springer Publishers, Heidelberg, Germany | 1993 |
Crist WM, Pullen DJ, Rivera GH Acute lymphocytic leukemias. Chapter in Clinical Pediatric Oncology, 4th Edition, Vietti TJ, Fernbach DJ eds. The CV Mosby Co., St. Louis, Toronto, 305-335, 1991 | 1991 |
Pullen DJ, Boyett JM, Crist WM, Falletta JM, Roper M, Dowell B, van Eys J, Jackson JF, Humphrey GB, Metzgar RS, Cooper MD Pediatric Oncology Group utilization of immunologic markers in the designation of acute lymphocytic leukemia subgroups: Influence on treatment response. In Annals of the New York Academy of Sciences vol 428, pp 26-48, 1984. (Presented New York Academy of Sciences "Conference on Technology Impact: Potential Directions for Laboratory Medicine", 9/21/83). Selected for inclusion in Year Book of Cancer, 1986, RC Hickey, GF Saunders, RL Clark and RW Cumley (eds), Year Book Medical Publishers, Inc, Chicago, pp 183-184 | 1984 |
Pullen DJ, Crist WM, Falletta JM, Boyett JM, Roper M, Dowell B, van Eys J, Humphrey GB, Head D, Brock BL, Blackstock R, Metzgar RS, Cooper MD A Pediatric Oncology Group classification protocol for acute lymphocytic leukemia (ALinC 13). Immunologic phenotypes and correlation with treatment results. In S Murphy and J Gilbert (eds), Leukemia Research: Advances in Cell Biology and Treatment. Elsevier, North Holland, Excerpta Medica Publishers, New York, pp 221-239, 1983. (Presented St. Jude Children's Research Hospital International Symposium on Leukemia Cell Biology and Therapy, 5/21/82, Memphis, TN.) | 1983 |
Pullen J Drug-induced thrombocytopenias. In Lusher JM, Barnhart MI (eds): Acquired Bleeding Disorders in Children, Abnormalities of Hemostasis, vol 3, New York, Masson, 1981, pp 49-63 | 1981 |
Letter to the Editor | |
Frankel LS, Wang YM, Shuster J, Nitschke R, Doering EJ, Pullen J ) The effect of early leukovorin rescue. J Clin Onco. 1984; 2(9):1072 | 1984 |
Electronic Publications | |
Pullen J (editor), Gidvani-Diaz V (editor), Aygun B, Carpenter S, Harper J, Herrington B, Hogan MJ, Kesselheim J, Rogers Z, Vik TA American Academy of Pediatrics Pediatric Review and Education Program in Pediatric Hematology/Oncology Published monthly online January through December 2016 | 2016 |
Pullen J (editor), Gidvani-Diaz V (editor), Aygun B Carpenter S, Harper J, Herrington B, Hogan MJ, Kesselheim J, Rogers Z, Vik TA American Academy of Pediatrics Pediatric Review and Education Program in Pediatric Hematology/Oncology Published monthly January through December 2015 | 2015 |
Pullen J (editor), Gidvani-Diaz V (editor), Aygun B, Carpenter S, Harper J, Herrington B, Hogan MJ, Kesselheim J, Rogers Z, Vik TA American Academy of Pediatrics Pediatric Review and Education Program in Pediatric Hematology/Oncology Published monthly January through December 2014 | 2014 |
Arceci RJ (editor), Pullen J (editor), Gidvani-Diaz V, Hogan MJ, Kanwar VS, Kim J, Leavey PJ, Levy AS, Robers Z, Stoffman JM, Vik TA American Academy of Pediatrics Pediatric Review and Education Program in Pediatric Hematology/Oncology Published monthly January through December 2013 | 2013 |
Arceci RJ (editor), Pullen J (editor), Gidvani-Diaz V, Hogan MJ, Kanwar VS, Kim J, Leavey PJ, Levy AS, Rogers Z, Stoffman JM, Vik TA American Academy of Pediatrics Pediatric Review and Education Program in Pediatric Hematology/Oncology. Published monthly online January through December 2012 | 2012 |
Arceci RJ (editor), Pullen J (editor), Gidvani-Diaz V, Hogan MJ, Kanwar VS, Kim J, Leavey PJ, Levy AS, Rodriguez-Cortez H, Rogers Z, Stoffman JM, Vik TA American Academy of Pediatrics Pediatric Review and Education Program in Pediatric Hematology/Oncology. Published monthly online January through December 2011 American Academy of Pediatrics Pediatric Review and Education Program in Pediatric Hematology/Oncology, 2011 | 2011 |
Presentations
National Meeting of Children's Miracle Network Sponsors/Participating Institutions Staff, Acceptance of CMN Caregiver Award, Children's Miracle Network, Orlando FL | 03/2008 |
State/Local Invited Seminars/Lectures, Low Risk Acute Lymphocytic Leukemia in Children: Background and Current Status, MS Chapter, American Academy of Pediatrics Pediatric Hematology/Oncology Festschrift, Jackson, MS | 02/2006 |
National and International Invited Seminars/Lectures, Children's Oncology Group Designation for Low Risk Group in Childhood Acute Lymphocytic Leukemia, American Society of Hematology Educational Workshop, San Francisco, CA | 12/2000 |
National and International Invited Seminars/Lectures, Near Triploid, Near Tetraploid B-Precursor Acute Lymphocytic Leukemia, International Acute Lymphocytic Leukemia Workshop, Sausalito, CA | 12/2000 |
National and International Invited Seminars/Lectures, Pediatric Oncology Group Hypodiploidy in B-Precursor ALL, Montevideo Intergroup Rare Chromosome Initiative in Childhood Acute Lymphocytic Leukemia, Ponte di Legno, Italy | 05/1999 |
Honors, Awards, and Recognition
Lifetime Achievement Award for Class of 1961, Tulane University School of Medicine | 2011 |
The University of MS Medical Center, in December 2010, established an endowed chair for the Division of Pediatric Hematology/Oncology (named the D. Jeanette Pullen Chair). Dr. Gail Megason, current director of the division, is the initial recipient of this chair | 2010 |
Recipient, Resolution "Commending the service of Dr. Jeanette Pullen for her work at the University of Mississippi Medical Center's Children's Cancer Clinic, upon receiving the Childre's Miracle Network Achievement Award", State of Mississippi Legislature, House of Representatives, MS House of Representatives | 2008 |
Recipient, National Library of Medicine/UMC Rowland Medical Library Women Physicians Local Legends Award | 2008 |
Recipient, Women's Fund of the Community Foundation of Greater Jackson Community Service Award | 2008 |
Recipient, Children's Miracle Network Caregiver Award, Children's Miracle Network | 2008 |
Pediatric Hematology/Oncology Festschrift, MS Chapter, American Academy of Pediatrics | 2006 |
Charter Member, UMMC Chapter of National Gold Humanism Society | 2005 |
Listing, Best Doctors in America | 2005 |
Co-Chair, COG ALL Biology Committee | 2000 |
Co-Chair, COG ALL Risk Group/Classification Subcommittee | 1998 |
Vice Chair, POG New ALL Committee | 1994 |
Blair E. Batson Meritorious Service Award, MS Chapter, Americal Academy of Pediatrics | 1991 |
Chair, POG New ALL Classification and Reference Laboratory Directors' Committee | 1981 |
Chair, POG New ALL Committee | 1981 |
Principal Investigator, POG/COG for UMMC | 1970 |
Alpha Omega Alpha, Tulane University School of Medicine | 1961 |
Study Coordinator, POG 7615, Modified LSA2-L2 Therapy, T-cell leukemia portion | |
Study Coordinator, POG 7865, Pilot Acute Lymphocytic Leukemia of Childhood (ALinC) 13-Classification Protocol | |
Study Coordinator, POG 7866, Pilot ALinC 13-Treatment Protocol | |
Study Coordinator, POG 8035/8036, Laboratory Subclassification and Evaluation of Treatment Reginebs in Acute Lymphoid Leukemia of Childhood, ALinC 13C+T Protocols | |
Study Coordinator, POG 8305, SIMAL 3 and 4 Laboratory Reclassification Protocol | |
Study Coordinator, POG 8600, ALinC 14 Classification Protocol | |
Study Coordinator, POG 9000, ALinC 15 Classification Protocol | |
Study Coordinator, POG 9400, ALinC 16 Classification Protocol | |
Study Coordinator, POG 9900, ALinC 17 Classification Protocol | |
Study Co-coordinator, POG 9201/9605/9406 ALinC 16 Treatment Protocols | |
Study Co-coordinator, POG 9705 and 9806 ALinC 17 treatment Pilot Protocols | |
Study Co-coordinator, POG 9904, 9905, 9906 ALinC 17 Treatment Protocols | |
Study Co-cordinator, POG 9907, ALinC 17 Classification Cytogenetics Protocol | |
Recipient, State of Mississippi Legislature's Higher Education Appreciation Day, Working for Academic Excellence (HEADWAE) Award - UMC Outstanding Faculty Member | 1889 |
Professional Membership and Service
American Academy of Pediatrics, Co-Editor (PREP Hematology/Oncology) and Board Member, PREP Hematology-Oncology Self-Assessment Online Series | 2009 - Present |
(Charter) UMMC Chapter of Gold Humanism Society, Member | 2005 - Present |
Subboard of Pediatric Hematology/Oncology of the American Board of Pediatrics, Member | 2000 - 2005 |
Data Safety Monitoring Committee, St. Jude Children's Research Hospital (Chair 1999-2002), Member | 1999 - 2007 |
American Society of Pediatric Hematology/Oncology, Member | 1991 - Present |
American Association of Cancer Research, Member | 1983 - Present |
American Society of Clinical Oncology, Member | 1981 - Present |
American Association of Cancer Education, Member | 1974 - Present |
American Society of Hematology, Member | 1972 - Present |
Pediatric Oncology Group/Children's Oncology Group, Member | 1970 - Present |
Fellow, American Academy of Pediatrics, Member | 1967 - Present |
Mississippi Chapter, American Academy of Pediatrics, Member | |
Mississippi State Medical Association, Member |
Committee Service
Task Forces for UMC Cancer Center Planning, Chair | 2002 - 2003 |
Task Forces for UMC Cancer Center Planning, Chair | 2002 - 2003 |
UMC Institutional Cancer Research Committee, American Cancer Society, Member | 1996 - 2006 |
UMC Institutional Cancer Research Committee, American Cancer Society, Member | 1996 - 2006 |
UMC Department of Pediatrics Research Committee, Member | 1989 - 2006 |
UMC Department of Pediatrics Research Committee, Member | 1989 - 2006 |
UMC Transfusion Committee, Member | 1988 - 1994 |
MEDICAL CENTER-INSTITUTIONAL REVIEW BOARD 2, Member | 1975 - Present |
UMC Clinical Cancer Activities Committee, Member | 1974 - 2005 |
UMC School of Medicine Cancer Research Advisory Committee, Member | 1971 - 1980 |
University of MS School of Medical Cancer Research Advisory Committee, Member | 1971 - 2008 |
Other Service
UMMC Scholarship Oversight Committees (two) for Pediatric Hematology/Oncology Fellows, Member | 07/2011 - 06/2014 |
UMMC Scholarship Oversight Committees (two) for Pediatric Hematology/Oncology Fellows, Chair | 07/2006 - 06/2010 |
Honorary Attending Physician, University of Mississippi Medical Center | 2006 - Present |
UMMC Children's Cancer Fund Board of Directors, Member | 2006 - Present |
Chief of Staff, University Hospital, Chief of Staff | 1985 - 12/1986 |
UMMC Children's Cancer Fund Board of Directors, Medical Advisor | 1979 - 2005 |
Attending Physician, University of Mississippi Medical Center | 07/1969 - 12/2005 |
Teaching Experience
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for Fellows | Fall 2017 |
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for Fellows | Winter 2017 |
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for Fellows | Summer 2017 |
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for Fellows | Spring 2017 |
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for Fellows | Fall 2016 |
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for Fellows | Winter 2016 |
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for Fellows | Summer 2016 |
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for Fellows | Spring 2016 |
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for Fellows | Winter 2015 |
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for Fellows | Spring 2015 |
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for Fellows | Fall 2014 |
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for Fellows | Summer 2014 |
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for Fellows | Spring 2014 |
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for Fellows | Winter 2014 |
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for Fellows | Fall 2013 |
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for Fellows | Spring 2013 |
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for Fellows | Summer 2013 |
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for Fellows | Winter 2013 |
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for Fellows | Fall 2012 |
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for Fellows | Summer 2012 |
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for Fellows | Spring 2012 |
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for Fellows | Winter 2012 |
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for Fellows | Fall 2011 |
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for Fellows | Summer 2011 |
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for Fellows | Spring 2011 |
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for Fellows | Winter 2011 |
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for Fellows | Fall 2010 |
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for Fellows | Summer 2010 |
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for Fellows | Spring 2010 |
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for Fellows | Winter 2010 |
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for Fellows | Fall 2009 |
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for Fellows | Summer 2009 |
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for Fellows | Spring 2009 |
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for Fellows | Winter 2009 |
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for Fellows | Fall 2008 |
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for Fellows | Summer 2008 |
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for Fellows | Spring 2008 |
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for Fellows | Winter 2008 |
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for Fellows | Fall 2007 |
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for Fellows | Summer 2007 |
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for Fellows | Spring 2007 |
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for Fellows | Winter 2007 |
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for Fellows | Fall 2006 |
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for Fellows | Summer 2006 |
Medicine, Small Group, Course Director, Pediatric Hematology/Oncology Instruction for Fellows | Spring 2006 |
Medicine, Small Group, Course Director, Pediatric HematologyOncology Instruction for Fellows | Winter 2006 |
Fellows supervised
Pediatric Hematology/Oncology Fellowship Training, Training Faculty, 9 fellows supervised, Weekly Teaching Sessions with Weekly Exams; Microscopy Teaching Sessions. | 01/2006 - Present |